

Special Communication

HIV Prevention in Clinical Care Settings

2014 Recommendations of the International Antiviral Society-USA Panel

Jeanne M. Marrazzo, MD, MPH; Carlos del Rio, MD; David R. Holtgrave, PhD; Myron S. Cohen, MD; Seth C. Kalichman, PhD; Kenneth H. Mayer, MD; Julio S. G. Montaner, MD; Darrell P. Wheeler, PhD, MPH; Robert M. Grant, MD, MPH; Beatriz Grinsztejn, MD, PhD; N. Kumarasamy, MD, PhD; Steven Shoptaw, PhD; Rochelle P. Walensky, MD, MPH; Francois Dabis, MD, PhD; Jeremy Sugarman, MD, MPH; Constance A. Benson, MD

IMPORTANCE Emerging data warrant the integration of biomedical and behavioral recommendations for human immunodeficiency virus (HIV) prevention in clinical care settings.

OBJECTIVE To provide current recommendations for the prevention of HIV infection in adults and adolescents for integration in clinical care settings.

DATA SOURCES, STUDY SELECTION, AND DATA SYNTHESIS Data published or presented as abstracts at scientific conferences (past 17 years) were systematically searched and reviewed by the International Antiviral (formerly AIDS) Society—USA HIV Prevention Recommendations Panel. Panel members supplied additional relevant publications, reviewed available data, and formed recommendations by full-panel consensus.

RESULTS Testing for HIV is recommended at least once for all adults and adolescents, with repeated testing for those at increased risk of acquiring HIV. Clinicians should be alert to the possibility of acute HIV infection and promptly pursue diagnostic testing if suspected. At diagnosis of HIV, all individuals should be linked to care for timely initiation of antiretroviral therapy (ART). Support for adherence and retention in care, individualized risk assessment and counseling, assistance with partner notification, and periodic screening for common sexually transmitted infections (STIs) is recommended for HIV-infected individuals as part of care. In HIV-uninfected patients, those persons at high risk of HIV infection should be prioritized for delivery of interventions such as preexposure prophylaxis and individualized counseling on risk reduction. Daily emtricitabine/tenofovir disoproxil fumarate is recommended as preexposure prophylaxis for persons at high risk for HIV based on background incidence or recent diagnosis of incident STIs, use of injection drugs or shared needles, or recent use of nonoccupational postexposure prophylaxis; ongoing use of preexposure prophylaxis should be guided by regular risk assessment. For persons who inject drugs, harm reduction services should be provided (needle and syringe exchange programs, supervised injection, and available medically assisted therapies, including opioid agonists and antagonists); low-threshold detoxification and drug cessation programs should be made available. Postexposure prophylaxis is recommended for all persons who have sustained a mucosal or parenteral exposure to HIV from a known infected source and should be initiated as soon as possible.

CONCLUSIONS AND RELEVANCE Data support the integration of biomedical and behavioral approaches for prevention of HIV infection in clinical care settings. A concerted effort to implement combination strategies for HIV prevention is needed to realize the goal of an AIDS-free generation.

JAMA. 2014;312(4):390-409. doi:10.1001/jama.2014.7999

◀ Editorial page 349

➕ Supplemental content at jama.com

➕ CME Quiz at jamanetworkcme.com and CME Questions page 430

Author Affiliations: Author affiliations are listed at the end of this article.

Corresponding Author: Jeanne M. Marrazzo, MD, MPH, Box 359932, Harborview Medical Center, 325 9th Ave, Seattle, WA 98104 (jmm2@uw.edu).

The availability of combination antiretroviral therapy (ART) has changed the lives of millions of individuals living with human immunodeficiency virus (HIV), transforming HIV from a fatal infection to a manageable chronic disease. Incidence of new HIV-1 infections worldwide has decreased by an estimated 33% since 2001 but remains high at approximately 2.3 million new infections in 2012. In the United States, approximately 50 000 new infections occur each year—a number that has remained largely unchanged since the 1990s.¹

The integration of biomedical and behavioral approaches to HIV prevention, coupled with ART for those infected, represents the cornerstone of efforts to curb the spread of HIV infection.² In an effort to provide practicing clinicians, public health experts, and policy makers with a framework to implement the best HIV prevention interventions, the International Antiviral Society—USA (IAS—USA) Panel has developed recommendations that integrate biomedical and behavioral prevention in the care of people living with or at risk for HIV infection. These recommendations are intended as best practice based on available evidence. Implementing these recommendations may present structural, economic, or political challenges. However, benefits to be derived from their implementation should contribute substantially to preventing disease progression, promoting healthy life years gained, and preventing new HIV infections.

In formulating these recommendations, the panel intentionally avoided distinguishing between behavioral and biomedical interventions, choosing to emphasize that providing prevention in care—for people living with or at risk for HIV infection—requires a combination of activities.

Methods

A systematic literature review using Medline and EMBASE was conducted to identify relevant published data. Specific search terms and limits are detailed in the supplemental section on the process of recommendation development (eMethods in the Supplement). Approximately 250 related manuscripts were selected based on scientific evidence or major guidelines. Panel members also conducted hand searches for newly published reports and abstracts from scientific conferences throughout the process. Data not published or presented in a peer-reviewed setting were not considered.

Recommendations were developed by the International Antiviral Society—USA HIV Prevention Recommendations Panel, an international panel of experts in HIV biomedical and behavioral science and practice. The panel convened in person in March 2013 and met regularly by teleconference thereafter. Panel members serve in a volunteer (no financial compensation) capacity and do not participate in industry promotional activities such as speaker bureaus, industry-paid lectures, or other marketing activities during panel membership (details available in the eMethods in the Supplement). Teams evaluated evidence and summarized panel discussions for each section. Prior to convening, members declared and discussed potential conflicts of interest and recused themselves from serving as section leaders or team members accordingly. A description of the panel process is included in the eMethods in the Supplement.

Panel recommendations were limited to HIV prevention for clinical care settings for nonpregnant adults and adolescents. Recommendations for prevention included ART that was available (approved by regulatory bodies or in expanded access [compassionate use]) or in late-stage development (new drug application filed). Recommendations were made by full-panel consensus and rated according to strength of the recommendation and quality of supporting data (Table 1 and Box 1).⁴ Ratings were provided only for recommendations supported by clinical or observational study data. The panel developed these recommendations regardless of clinical setting; thus, they are relevant to the global community. However, most of the cost-effectiveness literature cited is specific to the United States and other well-resourced settings, such as Canada, Western Europe, and Australia. To the extent that resource utilization, care structures, and ART costs vary widely across different settings, the economic discussions should be interpreted accordingly.

Section A. HIV Testing and Knowledge of Serostatus

Self-knowledge of HIV serostatus is the pivotal step in directing interventions to prevent HIV infection, enabling linkage of newly diagnosed persons to care as well as provision of prevention interventions to those found to be HIV-seronegative but at risk of infection. Despite the importance of this knowledge, approximately 50% of people living with HIV worldwide—and 16% of those in the United States—do not know their serostatus.⁵ Moreover, HIV-infected persons who are unaware of their serostatus may account for as much as 45% of new HIV infections in the United States.⁶ In addition, persons who receive a positive HIV test result often reduce their HIV-related risk behaviors.⁶⁻⁸

In 2006, the US Centers for Disease Control and Prevention (CDC) issued guidelines recommending routine opt-out HIV

Table 1. Strength of Recommendation and Quality of Evidence Rating Scale^a

Category/Grade	Definition
Strength of recommendation	
A	Strong support
B	Moderate support
C	Limited support
Quality of evidence	
Ia	Evidence from 1 or more randomized controlled clinical trials published in the peer-reviewed literature
Ib	Evidence from 1 or more randomized controlled clinical trials presented in abstract form at peer-reviewed scientific meetings
IIa	Evidence from nonrandomized clinical trials or cohort or case-control studies published in the peer-reviewed literature
IIb	Evidence from nonrandomized clinical trials or cohort or case-control studies presented in abstract form at peer-reviewed scientific meetings
III	Recommendation based on the panel's analysis of the accumulated available evidence

^a Adapted in part from the Canadian Task Force on the Periodic Health Examination.⁴

Box 1. Recommendations for Integrated Biomedical and Behavioral Approaches to HIV Prevention**A. HIV Testing and Knowledge of Serostatus**

All adults and adolescents should be offered HIV testing at least once.
Rating: AIII

To direct the need for additional testing, clinicians should periodically assess HIV-related risks, including sexual and drug-use activities, in all adults and adolescents.

Persons at higher risk (those engaging in risk behaviors or residing in areas of or testing at venues with high seroprevalence) should be tested more frequently, at intervals appropriate to the individual's situation.

All persons should be informed prior to undergoing HIV testing; however, pretest counseling should be sufficient only to meet the individual's needs and to comply with local regulations. The right to refuse testing must be honored, but clinicians should ensure that refusals are informed decisions. Rating: AIII

As the circumstances warrant and depending on the test used, at-risk persons who test HIV-seronegative should receive information about the possibility of a false-negative test result during the window period prior to appearance of detectable antibody and should be encouraged to obtain repeat testing at an appropriate time. Rating: AIIa

Approach to testing

Tests with the best performance (sensitivity/specificity) should be used.
Rating: AIIa

Rapid testing should be prioritized for persons less likely to return for their results. Rating: AIIa

Couples testing should be accommodated and encouraged. Rating: AIIa

Self-testing and home testing should be considered for those who have recurrent risk, difficulties with testing in clinical settings, or both. Rating: BIII

B. Prevention Measures Specific to HIV-Infected Individuals**Antiretroviral Therapy**

Clinicians should provide education about the personal health benefits of ART and the public benefits of prevention of transmission and should assess patients' readiness to initiate and adhere to long-term ART. Rating: AIII

ART should be offered on detection of HIV infection. Rating: AIIa

Strategies for adherence support should be implemented and tailored to individual patient needs or the setting. Rating: AIIa

Clinicians should be alert to the nonspecific presentation of acute HIV infection and urgently pursue specific diagnostic testing (plasma HIV viral load) if this is suspected. Rating: AIIa

Counseling on Risk Reduction, Disclosure of HIV Serostatus, and Partner Notification

Regular assessment of sexual and substance use practices should be performed in HIV-infected persons to direct individualized risk-reduction counseling, which should be delivered in combination with screening for sexually transmitted infection, condom provision, and harm reduction services (discussed below) for people who inject drugs, and integrated with strategies to maintain adherence. Rating: AIII

Assistance should be provided for patient- or clinician-based notification of sex and injection drug use partners to facilitate the patient's testing and linkage to care as well as efforts to disclose HIV infection to relevant partners and other key persons. Rating: AIII

Needle Exchange and Other Harm-Reduction Interventions Among People Who Inject Drugs

Simultaneous access to ART, needle and syringe exchange programs, supervised injection sites, medicalized heroin, and medically assisted therapy (which includes opioid-substitution therapy) should be provided to HIV-infected people who inject drugs. Rating: AIIa for each element; AIII for the combination

For individuals who use substances in ways other than injection, ART with adherence support and behavioral counseling should be provided. Rating: AIIa

C. Individual- and Structural-Level Interventions to Promote Movement of HIV-Infected Persons Through the Continuum of HIV Care: Additional Considerations

Linkage to HIV care for HIV-infected individuals is an essential component of expanded HIV testing and should be actively facilitated as soon as possible following a new diagnosis of HIV. Rating: AIIa

Strengths-based case management interventions in which patients identify and use personal strengths should be used to facilitate linkage to and retention in HIV care (examples available at <http://effectiveinterventions.org/en/HighImpactPrevention/PublicHealthStrategies/ARTAS.aspx>). Rating: AIIa

Additional patient support services are recommended, including patient health navigation, community and peer outreach, provision of culturally appropriate print media, verbal messages promoting health care utilization and retention from clinic staff, and youth-focused case management and support. Rating: AIIa

D. Prevention Measures Aimed at HIV-Uninfected Individuals**Risk Assessment and Risk Reduction for HIV Infection**

A specific risk assessment covering recent months should be conducted to determine the sexual and substance use practices that should be the focus of risk reduction counseling and appropriate risk reduction services should be offered. Rating: AIIa

For people at high risk for HIV infection who test HIV-seronegative, risk-reduction interventions or services are warranted, especially for individuals and couples who seek repeat HIV testing to monitor seroconversion. Rating: AIIa

Preexposure Prophylaxis

Daily FTC/TDF as preexposure prophylaxis should be offered to

Persons at high risk for HIV based on background incidence (>2%) or recent diagnosis of incident sexually transmitted infections, especially syphilis, gonorrhea, or chlamydia. Rating: AIIa

Individuals who have used postexposure prophylaxis more than twice in the past year. Rating: AIIa

People who inject drugs and who share injection equipment, inject 1 or more times a day, or inject cocaine or methamphetamines. Rating: AIIa

Preexposure prophylaxis should be part of an integrated risk-reduction strategy, so its use may become unnecessary if a person's behavior changed. Thus, clinicians should regularly assess their patients' risk and consider discontinuing preexposure prophylaxis if the sexual and partnering practices or injection drug use behaviors that involved exposure to HIV change. Rating: AIII

(continued)

Box 1. Recommendations for Combination HIV Prevention (continued)

HIV-infected persons should be asked about the HIV serostatus of their sexual partners, and preexposure prophylaxis should be discussed if they have regular contact with HIV-uninfected partners. Partners whose HIV serostatus is unknown should undergo counseling and testing. Considerations should include whether the infected partner's viral load is suppressed on ART, access to care for the uninfected partner, and coverage of associated costs. Rating: AIIb

HIV testing should be performed before starting preexposure prophylaxis, ideally with a sensitive, combination antigen-antibody assay capable of detecting acute or early infection (a fourth-generation assay), and regularly (monthly to quarterly depending on individual risk) thereafter. Screening for clinical symptoms that may signal acute infection should be performed. In suspected cases of acute HIV infection, plasma HIV viral load should be determined immediately and preexposure prophylaxis should be deferred until acute infection is ruled out. Rating: AIIa

Persons to be given TDF-based preexposure prophylaxis should have a creatinine clearance rate of at least 60 mL/min. Data are not available to inform a recommendation for preexposure prophylaxis for persons with a creatinine clearance rate of less than 60 mL/min. Rating: AIIa

Immunity to hepatitis B virus should be ensured for all persons initiating TDF-based preexposure prophylaxis. Rating: AIIa

Postexposure Prophylaxis

Postexposure prophylaxis should be offered to all persons who have sustained a mucosal or parenteral exposure to HIV from a known infected source as urgently as possible and, at most, within 72 hours after exposure. Rating: AIIb

The postexposure prophylaxis regimen should consist of the US Public Health Service–preferred regimen, which is currently FTC/TDF and raltegravir. Rating: BIIb

Women who receive postexposure prophylaxis should be offered emergency contraception to prevent pregnancy. Rating: BIIb

Persons who receive postexposure prophylaxis should be rescreened with a fourth-generation HIV antigen and antibody test 3 months after completion of the regimen. Rating: BIIb

Voluntary Medical Male Circumcision

Voluntary medical male circumcision should be recommended to sexually active heterosexual males for the purpose of HIV prevention, especially in areas with high background HIV prevalence. Rating: AIIa

Voluntary medical male circumcision should be discussed with men who have sex with men and who engage in primarily insertive anal sex, particularly in settings of high HIV prevalence. Rating: BIIb

Parents and guardians should be informed of the preventive benefits of male infant circumcision.³ Rating: BIIb

E. Prevention Issues Relevant to All Persons With or at Risk for HIV-1 Infection**Screening and Treatment for Sexually Transmitted Infections**

Routine, periodic screening for common sexually transmitted infections at anatomical sites based on sexual history should be performed (Box 2). Rating: BIIa

HIV-infected persons should be tested for hepatitis C virus at entry to care and assessed at regular intervals for related risks, including higher-risk sexual practices. Rating: BIIa

Quadrivalent human papillomavirus vaccination should be offered to all HIV-infected persons who fulfill the Advisory Committee for Immunization Practices criteria for its administration. Rating: AIIa

Immunity to hepatitis B virus should be ensured for all HIV-infected persons in care who have not already been infected with hepatitis B virus. Rating: AIIa

Routine screening for HSV-2 infection should be considered for HIV-infected persons who do not know their HSV-2 serostatus and wish to consider suppressive antiviral therapy to prevent transmission of HSV-2. Rating: CIIa

Reproductive Health Care: Hormonal Contraception

Current data are not sufficiently conclusive to restrict use of any hormonal contraception method, and women using progestin-only injectable contraception should be advised to also always use condoms and other HIV-preventive measures as feasible. In the interim, HIV-infected women should be counseled with regard to the availability of a range of options for family planning, including hormonal contraception. Rating: BIIa

Abbreviations: ART, antiretroviral therapy; FTC/TDF, emtricitabine/tenofovir disoproxil fumarate; HIV, human immunodeficiency virus; HSV-2, herpes simplex virus type 2.

testing in health care settings⁹; despite this, many missed opportunities for testing in clinical care continue to occur. In 2013, the US Preventive Services Task Force recommended routine HIV screening for all persons aged 15 to 65 years.¹⁰ Both of these guidelines note that where prevalence of undiagnosed HIV infection is 0.1% or less, routine screening may be supplanted by screening on the basis of risk assessment.

New developments such as HIV rapid tests, fourth-generation antibody and antigen assays (eTable in the Supplement),¹¹ fewer legal barriers to testing, and integration of screening in diverse settings should facilitate increases in HIV testing and early diagnosis, timely receipt of results, and better linkage to care.¹² Home- and community-based testing strategies, including self-testing, are especially important for populations with unmet health care needs.¹³ Fourth-generation assays allow clinicians to detect some acute and recent HIV infection, narrowing the window between infection and

diagnosis to approximately 15 to 20 days, thus allowing diagnosis of persons who are often highly infectious.¹⁴ New diagnostic algorithms also omit the need for routine confirmatory Western blot testing.¹⁵ The CDC Sexually Transmitted Disease Treatment Guidelines recommend that men who have sex with men (MSM) who have multiple or anonymous partners, have sex in conjunction with illicit drug use, use methamphetamine, or who have sex partners who participate in these activities be screened for sexually transmitted infections (STIs) and HIV more frequently (every 3 to 6 months) than MSM without such risk factors.¹⁶

For couples who are or plan to be sexually active, HIV testing is an effective intervention for both heterosexual and same-sex couples.^{17,18} With couples HIV testing, participants receive testing and counseling together; individuals learn not only of their own HIV serostatus but also that of their partner(s), which facilitates the delivery of tailored prevention messages and care plans.

Counseling associated with HIV testing is a complex topic. In the United States, state laws vary as to what is required.¹⁹ At a minimum, individuals should know that they are being tested. Some studies have found that counseling conducted at the time of HIV testing serves to reduce HIV-related risk behaviors and subsequent STIs; however, some studies did not demonstrate these effects.²⁰⁻³¹ Counseling should not be an impediment to HIV testing. Indeed, current guidance from the CDC states that prevention counseling should not be required with HIV diagnostic testing or as part of HIV screening programs in health care settings.⁹ Last, the economic value of HIV screening is well substantiated and is enhanced when transmission prevention benefits associated with screening are included.³²⁻³⁴

Brief risk assessment and brief clinically feasible risk reduction services may be considered for persons at high risk of HIV infection, including those with an incident STI, evidence of injection drug use, or who report sexual or drug using risk. In the sections below, we discuss these services both for persons living with HIV and for persons at increased risk for HIV infection (see Table 2 and 3).

For recommendations regarding HIV testing and knowledge of HIV status, see Box 1.

Section B. Prevention Measures Specific to HIV-Infected Individuals

Antiretroviral Therapy

Suppression of infectious HIV-1 in blood and genital secretions through provision of ART is highly effective in reducing—indeed, largely eliminating—the risk of ongoing HIV transmission. Observational studies of heterosexual couples have confirmed that successful ART reduces probability of HIV transmission.^{58,59} In 11 of 13 such studies, almost no HIV transmission was observed when the infected partner was receiving ART.^{60,61} In studies in which transmission events occurred despite ART, the HIV-infected participants were likely not reliably adherent to ART.⁶² The PARTNER study, a prospective observational study of 767 serodiscordant couples, 40% of which were same-sex male couples, recently reported no HIV transmission occurring during an estimated 894 couple-years of observation during which the majority of penetrative anal or vaginal sex was condomless, and where the HIV-infected partner was receiving ART.⁶³

The HPTN 052 (HIV Prevention Trials Network 052) study⁶⁴ was a randomized clinical trial (RCT) undertaken to prospectively determine the prevention benefit of ART. Among 1763 HIV serodiscordant couples in 9 countries, HIV transmission was reduced by more than 96% during a period of 18 months by adding ART to standard prevention strategies. The results also demonstrated a clinical benefit (reduction in incident tuberculosis) to individuals offered ART at CD4 cell counts greater than 350/ μ L compared with ART initiation at CD4 cell counts less than 250/ μ L.⁶⁵ An ecological study among people who inject drugs in Vancouver, British Columbia, Canada, suggested that ART significantly reduces spread of HIV infection.⁶⁶ In Kwazulu-Natal, South Africa, for every 1% increase in ART use, a 1.4% decrease in HIV incidence was observed.⁶⁷ An association of similar magnitude was established in a population-based analysis in British Columbia.^{66,68}

The President's Emergency Plan for AIDS Relief⁶⁹ and the World Health Organization (WHO)⁷⁰ now recommend that HIV-infected persons whose sex partners are HIV-uninfected be offered immediate initiation of ART, irrespective of CD4 cell count. The International Antiviral Society–USA⁷¹ and US Department of Health and Human Services⁷² recommend that ART initiation be offered to persons with HIV infection, regardless of CD4 cell count, for both individual health and transmission prevention benefits. Most recently, the WHO has recommended that ART be offered to all persons with CD4 cell counts less than 500/ μ L regardless of symptoms and with CD4 cell counts greater than 500/ μ L in a number of specific clinical settings.⁷⁰ Extrapolating from observed individual and population benefits, studies have demonstrated that in the United States, expanded screening (1 time in low-risk and annually in high-risk persons, such as those in serodiscordant partnerships or with multiple sex partners) with immediate ART initiation for individuals who test HIV-seropositive is a cost-effective method of preventing transmission.⁷³ Early ART targeted to HIV-serodiscordant couples has also been projected to be cost-effective in resource-limited settings.⁷⁴

Recent ecological analyses from areas where MSM are most affected by HIV infection have not reported declines in HIV incidence or prevalence as ART use has expanded, despite the encouraging data from the PARTNER study.^{63,75} Sustained HIV transmission from untreated (or inconsistently treated) MSM with high levels of plasma and genital HIV RNA is likely driving these epidemics.⁷⁵⁻⁷⁷

Acute and early HIV infection may limit the effect of ART on the prevention of HIV transmission. During this period, plasma and genital viral loads reach high concentrations and may remain elevated for several months. Very few people learn their serostatus during this period.⁷⁸ Newer HIV tests¹² and testing algorithms that incorporate HIV-1 RNA testing may enhance the likelihood of detection during this time, but the overall effect is likely to be small because the clinical diagnosis of acute HIV infection is frequently not suspected.⁷⁹ Because people with acute and early HIV infection contribute disproportionately to the spread of HIV,^{80,81} correct diagnosis and prompt intervention are needed.⁷ Small studies of the sexual behavior of people with early HIV infection do not suggest that behavior change alone will suffice; thus, immediate, lifelong ART is recommended.⁸² Early treatment preserves CD4 cell counts⁸³ and reduces ongoing viral diversification and the size of the viral reservoir.^{84,85} Moreover, failure to provide ART during a clinical encounter that occurs early in the disease can result in loss to follow-up with the patient, who may re-engage with care only when they have developed an HIV-related complication.⁸⁶

Adherence to ART is crucial for sustained HIV-1 suppression. Consistent with the current International Association of Physicians in AIDS Care guidelines, once-daily, fixed-dose combination ART is preferred whenever possible.^{71,72,87} Even with such regimens, complete adherence can be challenging. Behavioral interventions⁸⁸ that have shown promise include brief psychosocial counseling, such as cognitive behavioral therapy,⁸⁹⁻⁹³ risk-reduction behavioral interventions,⁴⁰ motivational interviewing,⁹³⁻⁹⁵ managed problem-solving counseling,⁹⁶ adverse-effects coping interventions,⁹⁷ peer-led social support groups,^{98,99} and counseling interventions for specific populations, including recently released inmates,¹⁰⁰ youth,¹⁰¹

Table 2. Centers for Disease Control Best and Good Levels of Evidence for Prevention Interventions for Persons Living With HIV/AIDS^a

Intervention Name	Design	Sample	Duration and Study Period	Major Outcomes	Level of Evidence per CDC ^b
CLEAR (adapted from Teens Linked to Care) ^{35,36}	Community-based, individual-level intervention RCT (telephone vs in-person vs delayed delivery) with 15-mo follow-up	175 Young PLWH at risk of substance abuse	Eighteen weekly 2-h sessions (1999-2002)	20-Percentage-point increase in protected sex acts with seronegative partners and 13-percentage-point increase in overall protected sex acts (in-person delivery)	Best
Eban ³⁷	Couple-based intervention RCT with group and single-couple sessions with 12-mo follow-up	535 African American serodiscordant couples (1070 individuals)	Eight weekly 2-h sessions (2003-2007)	63% Consistent condom use in intervention group compared with 48% in control group	Best
Healthy Living Project ³⁸	Community-based, individual-level intervention RCT with 5-, 10-, 15-, 20-, and 25-mo follow-up	936 PLWH considered at risk of transmitting	Fifteen 90-min sessions (2000-2002)	36% Reduction in risk acts between intervention and control groups at 20-mo follow-up	Best
Healthy Relationships ³⁹	Skill-based, small-group intervention RCT with 3- and 6-mo follow-up	332 PLWH	Five 2-h, twice-weekly sessions (1997-1998)	17 Percentage points higher in condom use for vaginal and anal sex acts in intervention group than in control group at 6-mo follow-up	Best
In the Mix ⁴⁰	Individual and group-level intervention RCT with 3-, 6-, and 9-mo follow-up	436 PLWH	One 45-min individual session, 5 2-h group sessions, 1 60-min individual session over 5 wk (2005-2009)	66% Fewer unprotected sex acts in intervention group than in control group at 6-mo follow-up ^c	Best
LIFT ⁴¹	Group-level intervention RCT (coping group vs support group) with 4-, 8-, and 12-mo follow-up	247 PLWH with history of childhood sexual abuse	Fifteen weekly 90-min sessions (2002-2004)	Coping group reduced unprotected sex acts by an average of 54% at 12-mo follow-up compared with support group	Best
Positive Choice: Interactive Video Doctor ⁴²	Computerized individual-level intervention RCT with 3- and 6-mo follow-up	476 PLWH	One computer-based session (2003-2006)	15% Fewer unprotected sex acts in intervention group than in control group at 6-mo follow-up	Best
Seropositive Urban Men's Intervention Trial (SUMIT) ⁴³	Group-level intervention (standard intervention vs enhanced intervention) RCT with 3- and 6-mo follow-up	811 HIV-seropositive MSM	Six 3-h, weekly sessions (enhanced), 1 1.5- to 2-h session (standard) (2000-2002)	5% Fewer participants reported unprotected acts of receptive anal sex in enhanced group than in standard group at 3-mo follow-up	Best
Treatment Advocacy Program (TAP) ⁴⁴	Individual-level primary care-based intervention RCT with 6- and 12-mo follow-up	313 HIV-seropositive MSM	Four 60- to 90-minute sessions over 8 wk, 3-mo check-in call, 2 15- to 90-min follow-up sessions at 6 and 12 mo (2004-2006)	20% Transmission risk in intervention group at 6- and 12-mo follow-up compared with 23%-25% in control group	Best
WILLOW ⁴⁵	Group-level intervention RCT with 6- and 12-mo follow-up	366 Sexually active HIV-seropositive adult women	Four 4-h, weekly sessions (1997-2000)	44% Reduction in mean number of unprotected vaginal sex acts (past 30 d) in intervention group compared with control group at 12-mo follow-up	Best
Options/Opciones Project ⁴⁶	Individual-level intervention randomized to study groups (intervention vs standard of care) with 18-mo follow-up period	497 PLWH	One 5- to 10-min session repeated at each clinic visit for 18 mo (2000-2003)	79% Decrease in average number of unprotected sex acts in intervention group over the 18-mo period ^a	Good
Partnership for Health ⁴⁷	Individual-level intervention randomized to study groups (gain-frame vs loss-frame vs attention-control) with 7-mo follow-up period	585 Sexually active PLWH	One 3- to 5-min session repeated at each clinic visit (1999-2000)	38% Decrease in unprotected sex acts among PLWH with 2 or more partners in loss-frame group at follow-up	Good
SafeTalk ⁴⁸	Individual-level intervention RCT with 4-, 8-, and 12-mo follow-up	490 PLWH	Four 40- to 60-min monthly sessions (2006-2009)	66% Reduction in unprotected sex acts in intervention group at 12-mo follow-up, compared with 30% reduction in control group ^a	Good
Together Learning Choices (TLC) ⁴⁹	Group-level intervention controlled trial with 9- and 15-mo follow-up	310 HIV-seropositive adolescent and young adult clinic patients	Twenty-three 2-h sessions delivered over 2 3-mo period (1994-1996)	82% Fewer unprotected sex acts in intervention group than in control group	Good

Abbreviations: CDC, Centers for Disease Control and Prevention; CLEAR, Choosing Life: Empowerment, Actions, Results!; HIV, human immunodeficiency virus; LIFT, Livelihoods & Food Security Technical Assistance; MSM, men who have sex with men; PLWH, people living with HIV/AIDS; RCT, randomized clinical trial; WILLOW, Women Involved in Life Learning from Other Women.

^a Adapted from CDC, 2013.⁵⁰ A recently published systematic review of risk

reduction interventions for PLWH provides additional detailed information on evidence-based and promising studies in the United States.⁵¹

^b The CDC evaluation of these interventions is a dynamic process; current information is available at <http://www.cdc.gov/hiv/dhap/prb/prs/index.html>; <http://www.effectiveinterventions.org/en/Home.aspx>.

^c Percentage reduction calculated from data presented in reference.

Table 3. Brief Behavioral Interventions for HIV-Uninfected Persons

Intervention Name	Design	Sample	Duration and Study Period	Major Outcomes	Level of Evidence per CDC ^a
Focus on the Future ⁵²	Individual-level intervention RCT (motivational interviewing, skill-building, condom information) with 3- and 6-mo follow-up	266 Young adult, African American, heterosexual men	One 45- to 50-min session (2004-2006)	Intervention group less likely to experience reinfection than control group (31.9% vs 50.4%), more likely to have used condoms in most recent intercourse than control group (72.4% vs 53.9%), and reported fewer sexual partners than control group (2.06 vs 4.15)	Best
Personalized Cognitive Risk-Reduction Counseling ²⁹	Individual-level counseling intervention RCT with 6- and 12-mo follow-up	248 MSM	One 1-h session (with optional diary) (1997-2000)	Reduction in participants reporting unprotected sex with nonprimary partners (66% baseline, 21% at 6-mo follow-up, 26% at 12-mo follow-up)	Best
Sister-to-Sister: One-on-One Skills Building ⁵³	Individual-level skill-building intervention RCT with 3-, 6-, and 12-mo follow-up	564 African American women	One 20-min session (1993-1996)	70% of intervention group reported practicing protected sex at 12-mo follow-up vs 62% of control group	Best
James et al ⁵⁴	Individual-level counseling (skills training) intervention 3-group RCT with 4- and 18-mo follow-up	492 Adults attending an STI clinic in the United Kingdom	One 20-min session (1991)	Intervention group more likely than control groups to carry condoms if they thought sex with a new partner was likely (71% vs 63% and 49%)	NA ^b
Mujer Segura ⁵⁵	Individual-level counseling intervention RCT with didactic control group with 6-mo follow-up	924 HIV-negative female sex workers in Mexico	One 35-min session	40% Decline in STI incidence in intervention group, 27.4 percentage point increase in condom use in intervention group compared with 17.5 percentage point increase in control group	NA ^b
Safe in the City ⁵⁶	Individual-level video intervention controlled trial randomized by location/time with 14 .8-mo average follow-up	38 635 Adults attending 1 of 3 STI clinics	One 23-min session (2003-2005)	4.9% Incidence of STIs in intervention group vs 5.7% in control group at 14 .8-mo follow-up	Best
Safer Sex ⁵⁷	Individual-level intervention RCT with 1-, 3-, 6-, and 12-mo follow-up	123 Adolescent girls with an STI	One 30-min or longer session (including a 7-min video) with booster sessions at follow-up appointments (1996-1999)	60% of intervention group reported protected sex at last sexual encounter at 12-mo follow-up vs 53% of control group	Good

Abbreviations: CDC, Centers for Disease Control and Prevention; NA, not applicable; RCT, randomized clinical trial; STI, sexually transmitted infection.

^a The CDC evaluation of these interventions is dynamic process; current

information is available at <http://www.cdc.gov/hiv/dhaph/prb/prs/index.html>; <http://www.effectiveinterventions.org/en/Home.aspx>.

^b The CDC ratings on level of evidence are assigned for US-based studies only.

urban-dwelling HIV-seropositive individuals with depression,¹⁰² and persons with low health literacy skills.^{103,104} Personalized telephone calls are effective, and computer-administered adherence promotion has shown promise.¹⁰⁵⁻¹⁰⁷ Among people who inject drugs, medication-assisted therapy and directly administered ART have improved adherence.^{108,109} For recommendations regarding the preventive benefits of ART, see Box 1.

Risk Reduction, Disclosure of HIV Serostatus, and Partner Notification

Behavioral interventions have been shown to reduce sexual risk behaviors, increase condom use, and reduce subsequent STIs among persons living with HIV (Table 3).^{35-51,110-116} The CDC has identified effective, evidence-based behavioral risk-reduction interventions developed for people living with HIV (Table 2).⁵⁰ As seen in Table 3, some of the "best" and "good" evidence (as labeled by the CDC) were developed before ART was widely available. A subset of these interventions has been subjected to economic evaluation and shown to be cost-effective.^{115,116} Further, some of the interventions described in Table 2 are brief and could be provided in a clinical setting, whereas others are more intensive and would likely be available only through other resources.

Although implementation of universal ART for HIV-infected persons remains incomplete, expanded use of ART at all stages of HIV infection has changed the dynamic between risk behaviors and how they are perceived. The effect of ART on sexual behavior is likely complex and depends on numerous factors at the individual level.⁵¹ Ongoing behavioral risk assessment is a critical component of care for persons with HIV and should inform a discussion of risk reduction. However, data indicate that despite evidence of benefit, only 61% of people living with HIV who engage in risk behavior with serodiscordant partners receive risk-reduction prevention services.¹¹⁷ Effective behavioral risk-reduction strategies are typically delivered using individualized counseling techniques, including motivational interviewing^{118,119} and skills-based counseling.^{120,121} In settings where such counseling cannot be delivered, clinicians should at minimum conduct a brief risk assessment^{122,123} and refer patients to available relevant health services. Risk screening protocols¹²⁴ may be useful to identify individuals in need of more intensive counseling in busy clinical settings¹²⁵ or to monitor for incident STIs¹²⁶ or clinical indications of injection drug use. Importantly, risks identified during these conversations should facilitate discussion about potential effects of ongoing risk behavior, even in the setting of successfully suppressed plasma HIV viral load. For example, inflammation caused by

genital STIs or other inflammatory processes can increase HIV-1 RNA levels in genital secretions even when plasma HIV is suppressed by ART, thus rendering the “fully suppressed” person potentially infectious.¹²⁷ In addition, superinfection (acquisition of a second HIV strain after an immune response to the initial strain has been established) may be relatively frequent in some populations and may be associated with poor clinical outcomes.¹²⁸ Last, treatment for HIV does not affect the risk for acquisition of other STIs.¹²⁹

Persons with HIV should receive guidance and support in disclosing infection status to sex and drug injection partners. In some jurisdictions, legislation that criminalizes HIV exposure may discourage HIV-infected persons from disclosure; thus, it is important to know the relevant legal context and to be aware of resources that may facilitate this process.¹³⁰ Some care settings have formalized HIV partner management programs and demonstrated enhanced effectiveness of partner elicitation and notification.^{131,132} If self-disclosure is used, factors to discuss are how to prepare for disclosure, to whom it will be made, when and how it will take place, how it can affect the client and persons to whom disclosure is made, and the stressful nature of the process.¹³³

For recommendations regarding risk reduction counseling, status disclosure, and partner notification, see Box 1.

Needle Exchange and Other Harm Reduction Interventions Among People Who Inject Drugs

Simultaneous scale-up of combining access to ART, opioid substitution therapy, and harm reduction services can greatly reduce the incidence of HIV infection among people who inject drugs, and is supported by technical guidelines from the WHO, United Nations Office on Drugs and Crime, and the Joint United Nations Programme on HIV/AIDS.¹³⁴⁻¹³⁶ In an ecological study in Vancouver, British Columbia, Canada, increased ART coverage corresponded with reduction in “community median plasma viral” load and an approximately 50% reduction in new HIV diagnoses, including those among people who inject drugs.⁶⁶ More recently, a population-based analysis in British Columbia demonstrated a greater than 90% province-wide decline in new diagnoses of HIV infection, which was largely attributed to the expansion of harm-reduction programs coupled with enhanced ART coverage among people who inject drugs.⁶⁸ Unfortunately, people who use drugs face widespread barriers to accessing ART in many settings.¹³⁷

Treatment for opiate addiction with opioid substitution therapies, especially methadone, increases the likelihood that people who inject drugs will initiate ART.¹³⁸ Once initiated, methadone maintenance increases ART adherence, including among homeless persons.¹³⁹ Opioid substitution therapies likely reduce HIV transmission by reducing illicit opioid use, sharing of injection equipment, numbers of sex partners, and exchange of sex for drugs or money.¹⁴⁰ In addition, there is no evidence of increased sexual risk behavior after initiating ART among people who inject drugs.^{141,142} Of note, use of opioid substitution therapies should be voluntary; coercive treatment does not prevent HIV transmission and does not treat addiction.¹⁴³

Needle and syringe exchange programs link individuals to health care services and provide sterile injection equipment and supplies, reducing associated transmission risks. No RCTs document efficacy for these programs, although observational reports support their use. Health outcomes among people who inject drugs living

in New York City when syringe exchange was legal were compared with those among people who inject drugs living in Newark, New Jersey, when exchange was illegal. People who inject drugs living in Newark had substantially higher prevalence rates of HIV, hepatitis C virus, and hepatitis B virus infections and more frequent self-reported needle reuse and sharing.¹⁴⁴ Access to a supervised injection facility is associated with improved individual health outcomes,¹⁴⁵⁻¹⁴⁷ risk behaviors,^{148,149} and societal outcomes.¹⁵⁰ Moreover, the use of medicalized heroin in a supervised injection facility has clinical benefit¹⁵¹ and is cost-effective.¹⁵²

In contrast, although most persons who use drugs take them by mouth, insufflation, smoking, or anal or vaginal insertion rather than injection, data that might inform HIV prevention strategies targeted at such noninjection drug use are limited. Approaches to HIV prevention for substance users are consistent with those used among non-substance users and should emphasize prevention of sexual transmission. Emerging data support novel strategies, including medications to treat stimulant dependence in MSM¹⁵³ and reduce risk behaviors in active stimulant users.¹⁵⁴ For recommendations regarding prevention in people who inject drugs, see Box 1.

Section C. Individual- and Structural-Level Interventions to Promote Movement of HIV-Infected Persons Through the Continuum of HIV Care: Additional Considerations

The HIV care continuum provides a representation of the steps necessary to take HIV-infected persons from diagnosis to suppression of plasma HIV-1 viral load. The value of investing in linkage to care after a new HIV diagnosis has been demonstrated.^{155,156} A model-based study demonstrated that investments along the most distal part of the care continuum (ensuring adherence, linkage, and retention) were more economically efficient than those devoted to increase HIV screening.¹⁵⁷

Moving individuals across the HIV care continuum can be arduous for those on the margins of the health care delivery system.^{158,159} Interventions that consider the individual's social environment and attendant structural factors produce more positive and sustainable outcomes compared with those that do not.¹⁶⁰ Commonly cited community or structural barriers include fear of being stigmatized because of an HIV diagnosis; joblessness resulting from disclosure; inability to afford health care; homelessness or unstable housing; incarceration; lack of a supportive social network; food insecurity; and legal, legislative, and policy factors that pose obstacles to addressing these concerns.^{161,162}

For these reasons, structural and community-level interventions (broadly defined as those that build on the awareness that environmental, social, political, and economic factors are potential sources of HIV risk and vulnerability) are increasingly important.¹⁶²

Linkage to Care

The period after a person is initially diagnosed with HIV represents a critical opportunity to establish linkage to care. Failure to do so reduces the opportunity to address current health issues, access preventive services, and initiate timely ART. However, data to inform interventions to ensure that this linkage is made are sparse. One RCT

Table 4. Completed Clinical Trials of Immediate Antiretroviral Therapy for HIV-Positive Partners and Medical Male Circumcision

Study	Sample Size	Population	Design	HIV Incidence	Protective Effect, % (95% CI)
Antiretroviral therapy for HIV+ partner					
HPTN 052 ⁶⁵	1763	HIV-serodiscordant couples (heterosexual and same sex)	Immediate ART vs deferred ART	Immediate ART: 0.1/100 py; control: 1.7/100 py	96 (73 to 99)
Medical male circumcision					
ANRS 1265 ¹⁷⁵	3274	HIV-seronegative men	Circumcision vs no circumcision	Immediate ART: 0.85/100 py; control: 2.1/100 py	60 (32 to 76)
Rakai ¹⁷⁶	4996	HIV-seronegative men	Circumcision vs no circumcision	Immediate ART: 0.66/100 py; control: 1.33/100 py	51 (16 to 72)
Kisumu ¹⁷⁷	2784	HIV-seronegative men	Circumcision vs no circumcision	Immediate ART: 2.1/100 py; control 4.2/100 py	53 (22 to 72)

Abbreviations: ART, antiretroviral therapy; HIV, human immunodeficiency virus; HPTN, HIV Prevention Trials Network.

evaluated a brief (up to 5 sessions) case management intervention focused on identifying individual strengths, reducing barriers to obtaining care, and accompanying persons to appointments. Compared with passive referral, the intervention was more effective in creating linkage to care.¹⁶³ Use of outreach efforts, financial incentives, navigation assistance, partner services, and social marketing have successfully engaged individuals from underserved and marginalized populations, including persons of color and MSM.¹⁶⁴⁻¹⁶⁶ Further research is needed to identify barriers to care and optimal strategies for increasing linkage to care. New approaches to program science should inform this process and are especially important in resource-limited settings.

Retention in Care

Consistent retention in care has been associated with shorter time to viral load suppression, lower cumulative viral load burden, improved immune function, decreased mortality, and decreased engagement in HIV transmission behaviors.^{167,168} A large observational study found that retention increased substantially after the implementation of clinic-wide interventions, including print reminders and brief verbal messages used by all clinic staff.¹⁶⁹ Patient navigation interventions, community and peer outreach, print media, verbal messages from clinic staff, financial incentives, and youth-focused case management and support have been associated with increased retention in care.^{107,170-173} For HIV-infected, opioid-dependent individuals, 1 RCT demonstrated that medication-assisted drug treatment (buprenorphine and naloxone) was associated with increased retention in care.¹⁷⁴ For recommendations regarding clinic-wide interventions, see Box 1.

Section D. Prevention Measures Aimed at HIV-Uninfected Individuals

Until recently, the prevention of HIV infection for uninfected individuals was focused only on behavioral interventions. Although these continue to be important, effective biomedical approaches are now available (see Table 4 and Table 5). Importantly, all biomedical prevention trials have also included state-of-the-art behavioral counseling as part of the approach. Thus, HIV prevention should not be considered as either behavioral or biomedical but rather as a combination intervention.

Risk Assessment and Risk Reduction for HIV Infection

There is strong evidence that brief behavioral counseling delivered to persons at risk for HIV infection reduces sexual risk behaviors, increases condom use, and reduces subsequent STIs including HIV.^{50,110-114,184-188} The EXPLORE Study, a multicity, randomized trial of a 10-session counseling intervention among MSM, demonstrated a 39% reduction in HIV incidence during a 12- to 18-month period after counseling and an 18% reduction in incidence during a 48-month period.^{189,190} These findings are bolstered by a meta-analysis of randomized trials that tested much briefer, single-session sexual risk reduction counseling interventions that embodied similar principles of behavior change.¹⁹¹ Reductions in incident STIs have been demonstrated to result from brief interventions of skills-based individualized counseling in trials with high-risk men and women, and a number have been labeled as "best" or "good" evidence-based interventions by CDC (Table 3).^{29,50,52-57} Not surprisingly, interventions that involved a longer duration of a single counseling session were more effective than those of briefer duration. Face-to-face counseling interventions also had greater effects than media-delivered messages. Risk reduction counseling can be delivered alone or ideally in combination with biomedical prevention strategies targeting HIV-uninfected persons.^{6,50,192,193}

The most effective individualized counseling provides patients with self-management skills and condoms.^{110,194,195} In addition, content analyses of effective counseling have identified common principles that promote preventive behaviors: fostering a sense of self-belief and self-worth, distinguishing fact from myth, evaluating options and consequences, formulating commitment to change, planning skills, promoting self-control, establishing pleasurable alternatives to high-risk sexual activity, negotiating safer behaviors, setting limits, and acting to help others protect themselves.¹⁹⁶ Although various counseling approaches have nuances tailored to particular populations and service settings, most are well suited for use in combination with biomedical prevention technologies. For recommendations regarding risk reduction counseling for HIV-uninfected persons, see Box 1.

Preexposure Prophylaxis

Preexposure prophylaxis (PrEP) with daily oral emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) as a fixed-dose combination decreases HIV-1 acquisition among MSM,¹⁸¹ serodiscordant het-

erosexual couples,¹⁷⁸ and heterosexual adults¹⁷⁹ (Table 5). Daily oral TDF alone was effective for preexposure prophylaxis in heterosexual couples¹⁷⁸ and people who inject drugs.¹⁸⁰ The US Food and Drug Administration approved daily oral FTC/TDF for HIV prevention in 2013, and the CDC has issued guidance for its use.¹⁹⁷

The key determinant of preexposure prophylaxis efficacy is medication adherence. Detection of TDF in plasma has been associated with reduction in HIV acquisition by approximately 90% among MSM and heterosexual adults.^{178,179,181} Detection of TDF in

peripheral blood mononuclear cells commensurate with daily use was associated with an estimated 99% reduction in HIV risk (95% CI, 96% to >99%).¹⁹⁸ In contrast, no efficacy was discerned in 2 trials in which TDF was generally detected in less than 30% of female participants.^{182,183}

Clinical trial findings highlight important considerations for pre-exposure prophylaxis implementation, including the development of drug resistance among participants experiencing acute retroviral infection at enrollment, underscoring the need to rule out acute

Table 5. Completed Clinical Trials of Preexposure Prophylaxis With Antiretroviral Drugs

Study (Location)	Population	Design	Relative Reduction in HIV Incidence in Intention-to-Treat Analysis	Preexposure Prophylaxis Detection in Blood Samples From Nonseroconverters	HIV Protection Estimate as Related to Adherence	Safety
Partners PrEP Study ¹⁷⁸ (Kenya, Uganda)	4747 Heterosexual men and women with known HIV-infected partners, serodiscordant couples	1:1:1 Randomization to daily oral TDF, FTC/TDF, or placebo	TDF: 67% (95% CI, 44% to 81%) FTC/TDF: 75% (95% CI, 55% to 87%)	81%	86% (TDF), 90% (FTC/TDF) in participants with detectable tenofovir levels	No significant differences in the frequency of death, serious adverse events, or serum creatinine or phosphorus level abnormalities between study groups Increased creatinine levels and decreased phosphorus levels in less than 1% of all patients
TDF2 Study ¹⁷⁹ (Botswana)	1219 Heterosexual men and women	1:1 Randomization to daily oral FTC/TDF or placebo	FTC/TDF: 63% (95% CI, 22% to 83%)	79%	78% Excluding follow-up periods when participants had no PrEP refills for 30 d	FTC/TDF group had higher rates than the placebo group of nausea (18.5% vs 7.1%; <i>P</i> < .001), vomiting (11.3% vs 7.1%; <i>P</i> = .08), and dizziness (15.1% vs 11.0%; <i>P</i> = .03); all events were grade 1 and lessened after the first mo Serious adverse event and laboratory adverse event rates were similar between the study groups Significant decline in bone mineral density in the FTC/TDF group vs the placebo group
Bangkok Tenofovir Study ¹⁸⁰ (Thailand)	2413 Injection drug users	1:1 Randomization to TDF or placebo	TDF: 48.9% (95% CI, 9.6% to 72.2%)	NA	NA	Nausea more common in the tenofovir group vs the placebo group (8% vs 5%; <i>P</i> = .02) Similar frequency of death, serious adverse events, and grade 3 or 4 laboratory results between the study groups
iPrEx ¹⁸¹ (Brazil, Ecuador, Peru, South Africa, Thailand, United States)	2499 MSM and transgender women	1:1 Randomization to daily oral FTC/TDF or placebo	FTC/TDF: 44% (95% CI, 15% to 63%)	51%	92% In participants with detectable tenofovir or emtricitabine levels; 99% if tenofovir concentrations were commensurate with daily dosing	Similar rates of serious adverse events between the study groups Nausea more frequent during the first 4 wk in the FTC/TDF group vs the placebo group (2% vs <1%; <i>P</i> < .004) Creatinine elevations (any grade) 2% in the FTC/TDF group vs 1% in the placebo group (<i>P</i> = .08); majority of the events grade 1
FEM-PrEP ¹⁸² (Kenya, South Africa, Tanzania)	2120 Women	1:1 Randomization to daily oral FTC/TDF or placebo	FTC/TDF: 6% (95% CI, -52% to 41%); no statistically significant reduction in HIV incidence	35%-38% at a single visit, 26% at 2 consecutive visits surrounding the infection period	Use of PrEP too low to evaluate efficacy	TDF/FTC group had significantly higher rates than the placebo group of nausea (4.9% vs 3.1%; <i>P</i> = .04), vomiting (3.6% vs 1.2%; <i>P</i> < .01), or elevated alanine aminotransferase levels (11.4% vs 8.6%; <i>P</i> = .03)
VOICE ¹⁸³ (South Africa, Uganda, Zimbabwe)	3019 Women (plus 2010 women receiving tenofovir or placebo gel)	1:1:1 Randomization to daily oral FTC/TDF, oral TDF, or placebo	TDF: HR, 1.49 (95% CI, -129% to 3%); <i>P</i> = .07 FTC/TDF: HR, 1.04 (95% CI, -49.16% to 26.98%; NS)	≤30% of samples; ≥50% of women never had detectable tenofovir in any sample	Use of PrEP too low to evaluate efficacy	Similar frequencies of serious and laboratory adverse events compared with placebo No differences in confirmed phosphorus, transaminase, or urine protein/glucose level abnormalities

Abbreviations: FEM-PrEP, Preexposure Prophylaxis Trial for HIV Prevention Among African Women; FTC, emtricitabine; HR, hazard ratio; iPrEx, Chemoprophylaxis for HIV Prevention in Men; MSM, men who have

sex with men; NA, not available; NS, not statistically significant; TDF, tenofovir disoproxil fumarate; VOICE, Vaginal and Oral Interventions to Control the Epidemic.

infection prior to starting preexposure prophylaxis. Resistance to TDF/FTC was not observed^{178,179,181} or was rare¹⁸² in infections that developed after starting preexposure prophylaxis.¹⁷⁸⁻¹⁸³ Importantly, trial participants who received regular risk assessment and counseling did not exhibit an increase in risk behaviors.^{178,179,181} Observational cohort studies of persons receiving open-label preexposure prophylaxis are under way and should provide important information about risk compensation now that preexposure prophylaxis efficacy is known.

Despite these encouraging results, unanswered questions remain. Although daily oral FTC/TDF is the only preexposure prophylaxis regimen that is approved by the Food and Drug Administration, oral TDF alone is effective and does not confer a risk of resistance to FTC.^{178,179} New CDC preexposure prophylaxis guidelines suggest the potential for "off-label" use of TDF alone in serodiscordant couples and people who inject drugs, based on trial data.¹⁹⁷ Nondaily use of oral FTC/TDF was efficacious in nonhuman primates but has not been fully evaluated in humans.¹⁹⁹ Daily use of preexposure prophylaxis has advantages over nondaily dosing, including achievement of consistently higher levels of drug, greater tolerance of occasional missed doses, and establishment of a pill-taking routine.²⁰⁰ Although oral FTC/TDF is active against hepatitis B virus, there is a risk of hepatitis flare if active agents are stopped, especially in persons with cirrhosis. Thus, hepatitis B virus-uninfected persons should ideally begin vaccination prior to preexposure prophylaxis initiation.

Other antiretroviral drugs are theoretically well suited for preexposure prophylaxis, and long-acting preparations or sustained delivery systems administered parenterally or topically (eg, in a vaginal ring) may address the challenge of daily adherence. The efficacy of directly applied topical agents was supported by the results of the CAPRISA (Centre for the AIDS Programme of Research in South Africa) 004 trial, which showed benefit from use of vaginal 1% tenofovir gel before and after sex.²⁰¹ However, daily use of this regimen was not successful in the VOICE (Vaginal and Oral Interventions to Control the Epidemic) trial, likely because of low rates of adherence to the product.¹⁸³ A major challenge is to identify research and regulatory pathways for evaluating preexposure prophylaxis regimens. A surrogate marker for prophylactic efficacy is not yet available, although drug concentrations and tissue culture systems to assess viral replication appear promising.

Economic evaluations generally suggest that preexposure prophylaxis could be cost-effective in the United States but only if used among MSM at highest risk (annual incidences >2%).^{202,203} Shorter durations of use, improved adherence and efficacy, and decreased drug costs would enhance the economic attractiveness of preexposure prophylaxis for MSM. Even so, studies generally indicate that although cost-effective, the financial burden of a preexposure prophylaxis program could be substantial. For example, use of preexposure prophylaxis among high-risk MSM for 20-year duration could lead to an incremental increase in US health care costs of up to \$75 billion.²⁰³ For recommendations regarding preexposure prophylaxis, see Box 1.

Postexposure Prophylaxis

Nonhuman primate models suggest that antiretroviral postexposure prophylaxis (PEP) is highly effective in preventing infection after retroviral challenge.²⁰⁴ Although RCTs evaluating efficacy of post-

exposure prophylaxis have not been feasible, a retrospective case-control study of health care workers found that those who used zidovudine after an occupational exposure were 81% less likely to become HIV-infected than those who did not.²⁰⁵ The CDC subsequently developed guidelines for use of postexposure prophylaxis in occupational²⁰⁶ and nonoccupational²⁰⁷ settings. Postexposure prophylaxis is generally safe, and its use was associated with decreased HIV acquisition in a study comparing MSM in Brazil who used postexposure prophylaxis compared with those who did not.²⁰⁸ However, studies among MSM in America and Australia²⁰⁹ have suggested that some individuals may not accurately estimate their risk, leading to HIV acquisition despite availability of postexposure prophylaxis. Given the challenge of obtaining postexposure prophylaxis quickly and because animal studies suggest greater protection if postexposure prophylaxis is administered prior to retroviral challenge, individuals at repeated risk for HIV acquisition may benefit from postexposure prophylaxis.

Nonoccupational postexposure prophylaxis should only be administered to individuals who have had mucosal contact with infected blood or genital secretions or to health care workers who have needle stick exposures to HIV-infected source patients.²¹⁰ Clinicians should determine whether a given exposure could result in HIV transmission and whether the source partner was HIV-infected or of unknown serostatus but at high risk of being infected. If the source is known to be HIV-infected, ascertainment of specific ART use and HIV drug resistance in the index case should inform selection of ART for postexposure prophylaxis. Postexposure treatment should include 3 medications that are least likely to be affected by drug resistance.

The US Public Health Service currently recommends initiation of a 3-drug regimen for occupational postexposure prophylaxis,²⁰⁶ and this should be considered for sexual and parenteral exposures. Postexposure prophylaxis should be initiated as soon as possible, not more than 72 hours after a high-risk exposure.^{206,211} Animal studies support the use of postexposure prophylaxis for a duration of 28 days.²¹¹

The updated guidelines for postexposure prophylaxis recommend FTC/TDF and raltegravir as the initial regimen.²⁰⁶ TDF-based postexposure prophylaxis regimens are better tolerated than those containing zidovudine.^{212,213} A recent study of FTC/TDF and raltegravir as postexposure prophylaxis found that the most common adverse effects included nausea or vomiting (27%), diarrhea (21%), and headache (15%).²¹³ When choosing postexposure prophylaxis regimens, tolerability must be considered to ensure regimen adherence.²¹⁴ However, with access to newer antiretroviral drugs that are better tolerated, and with increased potential resistance in the community, adding a third drug is reasonable. The inclusion of an HIV protease inhibitor increases the likelihood of adverse effects.²¹⁵

Postexposure prophylaxis provides an opportunity to engage persons who have recurring high-risk exposure and to offer appropriate risk-reduction strategies.²¹⁶ These may include referrals to address patterns of sexual risk and substance use. In addition, clinicians should consider risk-based screening for concomitant STIs and the need for emergency contraception. Persons who initiate postexposure prophylaxis should be followed up for 6 months after completion of the regimen if conventional antibody testing is used and for 4 months if newer fourth-generation assays containing p24 antigen are used.²⁰⁶ For recommendations regarding postexposure prophylaxis, see Box 1.

Voluntary Medical Male Circumcision

Voluntary male circumcision reduces the risk of heterosexual HIV acquisition by 53% to 60%,¹⁷⁵⁻¹⁷⁷ an effect that is durable,²¹⁷ measurable at population level,²¹⁸ and cost-effective.^{219,220} The procedure also decreases transmission of genital human papilloma virus²²¹ and herpes simplex virus type 2.²²² Adult male circumcision has not been associated with direct protection of female partners,²²³ but with wider implementation, whole populations will likely benefit.²²⁴ Observational studies in Africa involving large numbers of neonates have also found male circumcision to be safe.^{225,226}

The WHO and Joint United Nations Programme in HIV/AIDS recommend voluntary male circumcision for HIV prevention in priority countries in sub-Saharan Africa with generalized epidemics and low prevalence of male circumcision. More than 1 million men have undergone this procedure as part of HIV prevention programs.²²⁷ Despite the recommendations, efforts to promote male circumcision in priority countries have had mixed results, likely because of limited health care resources and cultural attitudes toward circumcision. The need to simplify the procedure in resource-limited settings has led to development of medical devices that require minimal or no surgery, introduction of new, more efficient procedures that increase productivity by task shifting (a process of delegation whereby tasks are moved, when appropriate, to less specialized health workers), use of diathermy^{228,229} for hemostasis, and use of prepackaged surgical instruments. In some countries, demand from men has been low, and changes in the delivery system alone will not achieve the levels targeted. Political leadership has been critical to expansion efforts.²³⁰

Although no trials of adult male circumcision have been conducted among MSM, some epidemiologic data suggest that the procedure might be protective for MSM who engage in primarily insertive anal sex.²³¹ For recommendations regarding male circumcision, see Box 1.

Section E. Prevention Issues Relevant to All Persons With or at Risk for HIV-1 Infection

Screening and Treatment for Sexually Transmitted Infections

Genital STIs facilitate transmission and acquisition of new HIV infection. Among HIV-uninfected partners in serodiscordant heterosexual couples, the presence of herpes simplex virus type 2 seropositivity, trichomoniasis, genital ulcer disease, cervicitis, or vaginitis substantially increased risk of HIV-1 acquisition, irrespective of the infected partner's plasma viral load.²³² Early syphilis and anorectal STIs are associated with high risk for concurrent or subsequent HIV acquisition.^{126,233}

Interventions to detect and treat STIs identify persons at highest risk for sexual acquisition and transmission of HIV and can prioritize delivery of risk-reduction interventions, especially preexposure prophylaxis. The CDC and the HIV Medicine Association recommend routine screening for common STIs, including syphilis, gonorrhea, and chlamydia infections, for persons at high risk for HIV acquisition, particularly MSM.^{16,234} A relevant sexual history should, in turn, direct STI screening toward specific anatomical sites and screening for sexual acquisition of hepatitis C virus, which is associated with high-risk anal sex practices.²³⁵ Routine laboratory screening for common STIs among MSM is summarized in Box 2.

For people living with HIV, sexual health, including prevention and detection of STIs, has become an important component of primary care.²³⁴ Recent trends indicate an increase in syphilis and gonorrhea among some HIV-infected persons, particularly MSM, and that incident hepatitis C is increasing in this group as well.^{129,236-239} Despite this, routine screening for STIs in the HIV care setting is low.²⁴⁰ Behavioral assessments should direct appropriate screening for common STIs, including syphilis, gonorrhea, and chlamydia, at exposed anatomical sites (pharynx, rectum, and urethra).¹⁶ Because many syphilis cases are latent (positive serology in the absence of clinical signs), serologic screening is crucial. Last, the quadrivalent human papillomavirus vaccine is safe and immunogenic in HIV-infected persons and should be offered routinely.²⁴¹⁻²⁴³ For recommendations regarding STI screening and prevention, see Box 1 and Box 2.

Reproductive Health Care: Hormonal Contraception

Unintended pregnancy is a considerable burden for many women and their families, and access to safe, effective, and acceptable contraception is critical. For reproductive-aged women living with HIV, it is especially important as a means to plan pregnancy with intent to prevent vertical HIV-1 transmission and ensure maternal health. Use of hormonal contraception does not affect HIV disease progression among HIV-infected women or the likelihood of HIV transmission to male partners, nor is there an increase in the recognized adverse effects of use of hormonal contraception in women with HIV relative to those without HIV.^{244,245}

Some observational studies have raised concern about a potentially increased risk of HIV acquisition among users of specific hormonal contraception methods, primarily depot-medroxyprogesterone acetate (DMPA), but results overall are inconsistent and study quality varies.²⁴⁶ In studies that reported an association, the relative risk was generally in the 1.5 to 2 range. A recent modeling analysis concluded that unless the true effect size approaches more than double the risk, it is unlikely that reductions in injectable hormonal contraceptives could result in a public health benefit, except possibly in those countries in southern Africa with the largest HIV epidemics.²⁴⁷ A systematic review recently summarized available analyses of various methods of hormonal contraception in terms of the risk of HIV acquisition.²⁴⁶ The authors concluded that data do not suggest that hormonal contraceptive pills are associated with an increased risk of HIV acquisition. For injectable hormonal contraceptives, no data suggest a close association between norethisterone enanthate (NET-EN) and HIV acquisition, although data are limited.²⁴⁸ Some observational data raise concern about a potential association between use of depot-medroxyprogesterone acetate and risk of HIV acquisition. There are almost no data on whether methods such as contraceptive implants, patches, rings, or hormonal intrauterine devices may impact risk of HIV acquisition.

During a 2012 WHO technical consultation, experts reviewed all available biological, epidemiologic, and modeling data and recommended that the WHO continue to suggest no restriction on use of any method of hormonal contraception; however, they noted that for women at high risk of HIV infection, condom use and other HIV preventive measures should be strongly emphasized for those using progestogen-only injectable contraception.²⁴⁹ The CDC subsequently updated its medical eligibility criteria for contraceptive use to reflect this stance for women in the United States.²⁵⁰ For recommendations regarding hormonal contraception, see Box 1.

Box 2. Approach to Screening for Sexually Transmitted Infections in HIV-Infected Patients**First Visit****All Patients**

Syphilis serologic testing

Nontreponemal test: RPR, VDRL

Treponemal test: EIA, CIA

Gonorrhea

Men: urine NAAT

Women: vaginal swab (preferred), cervical swab, or urine NAAT

Chlamydia

Men: urine NAAT

Women: vaginal swab (preferred), cervical swab, or urine NAAT (especially if sexually active and aged 25 years or younger, regardless of symptoms)

HSV-2 serologic testing

Type-specific (glycoprotein G-based) serology (consider)

Women

Trichomoniasis: vaginal swab NAAT (preferred); culture or rapid antigen detection test of vaginal fluid

Patients Reporting Receptive Anal Sex

Gonorrhea: rectal culture or NAAT if performed at laboratory with validation

Chlamydia: NAAT if performed at laboratory with validation

Patients Reporting Receptive Oral Sex

Gonorrhea: pharyngeal culture or NAAT if performed at laboratory with validation

Subsequent Routine Visits**Annually**

Repeat first-visit tests for all sexually active patients

More Frequently

Periodic screening at 3- or 6-month intervals may be appropriate depending on patient's reported risk factors or interim detection of other STIs

Presence of any of the following reported risk factors should prompt consideration of repeated STI screening:

Multiple partners

Anonymous partners

Interim diagnosis of new STIs

Substance use, especially methamphetamine use

Unprotected sex outside of a mutually monogamous relationship

Exchange of sex for drugs or money, or sex with a partner who reports these behaviors

High prevalence of STIs in the affected patient population

Life changes such as dissolution of a relationship that might promote adoption of high-risk sexual behaviors

EIA indicates enzyme immunoassay; CIA, chemiluminescent immunoassay; NAAT, nucleic acid amplification test; RPR, rapid plasma reagin; STI, sexually transmitted infection; VDRL, Venereal Disease Research Laboratory.

Conclusions

After more than 30 years, we are at a potential turning point in the control of the global HIV epidemic. With enhanced access to effective ART and durable viral suppression, nearly all persons living with HIV could be rendered noninfectious. Those without HIV

but at risk for infection can access prevention interventions ranging from ART-based preexposure prophylaxis to voluntary medical male circumcision. These biomedical interventions can be productively complemented by appropriate behavioral and structural interventions and support services. Clinicians are crucial in implementing these interventions, and should use evidence-based HIV prevention tools.

ARTICLE INFORMATION

Author Affiliations: University of Washington, Seattle (Marrazzo); Emory University, Atlanta, Georgia (del Rio); The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland (Holtgrave); University of North Carolina at Chapel Hill (Cohen); University of Connecticut, Storrs (Kalichman); Harvard Medical School, Boston, Massachusetts (Mayer); University of British Columbia, Vancouver (Montaner); Loyola University Chicago, Chicago, Illinois (Wheeler); University of California San Francisco (Grant); Evandro Chagas Clinical Research Institute (IPEC)-FIOCRUZ, Rio de Janeiro, Brazil (Grinsztejn); YR Gaitonde Centre for AIDS Research and Education, Chennai, India (Kumarasamy); University of California Los Angeles (Shoptaw); Massachusetts General Hospital, Boston (Walensky); Université de Bordeaux, Bordeaux, France (Dabis); The Johns Hopkins University, Baltimore, Maryland (Sugarman); University of California San Diego (Benson).

Author Contributions: Drs Marrazzo and del Rio had full access to all of the data in the study and

take responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: Marrazzo, del Rio, Holtgrave, Cohen, Kalichman, Montaner, Wheeler, Grant, Kumarasamy, Shoptaw, Dabis, Benson.

Acquisition, analysis, or interpretation of data: Marrazzo, Holtgrave, Mayer, Montaner, Grant, Grinsztejn, Walensky, Dabis, Sugarman, Benson.

Drafting of the manuscript: Marrazzo, del Rio, Holtgrave, Kalichman, Mayer, Montaner, Wheeler, Grant, Grinsztejn, Shoptaw, Dabis, Benson.

Critical revision of the manuscript for important intellectual content: Marrazzo, del Rio, Holtgrave, Cohen, Kalichman, Montaner, Wheeler, Grant, Kumarasamy, Shoptaw, Walensky, Dabis, Sugarman, Benson.

Statistical analysis: Holtgrave.

Administrative, technical, or material support: Marrazzo, Holtgrave, Grinsztejn, Kumarasamy, Benson.

Study supervision: Marrazzo, del Rio, Holtgrave, Cohen, Montaner, Benson.

Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Disclosure information represents the previous 3 years (updated May 20, 2014). Dr Marrazzo has served as a consultant to Merck and Astra-Zeneca; Dr del Rio has no conflicts to disclose; Dr Holtgrave's institution, The Johns Hopkins Bloomberg School of Public Health, has received research funds from Johnson and Johnson and Female Health Company; Dr Cohen has served as a consultant to Janssen Global Services and Roche Molecular Systems, Inc; Dr Mayer's institution, Fenway Health, has received research grants from Gilead Sciences and Merck; Dr Montaner's institution, BC-Centre for Excellence in HIV/AIDS at Providence Health Care and the University of British Columbia, has received research grants from AbbVie, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck, and ViiV Healthcare; Dr Kalichman has no conflicts to disclose; Dr Wheeler has no conflicts to disclose; Dr Grant has served as a consultant to Siemens Healthcare and ViiV Healthcare, and his institution, the University of

California San Francisco, has received support from Gilead Sciences for travel, accommodation, and meeting expenses; Dr Grinsztejn has no conflicts to disclose; Dr Kumarasamy has no conflicts to disclose; Dr Shoptaw has no conflicts to disclose; Dr Walensky has no conflicts to disclose; Dr Dabis has no conflicts to disclose; Dr Sugarman has no conflicts to disclose; Dr Benson's spouse has received research support from Bristol-Myers Squibb and Boehringer Ingelheim Pharmaceuticals, Inc, and has served as a scientific advisor to CytoDyn and Merck & Co, Inc, as a scientific advisory board member for Gilead Sciences, Inc, Globelimmune, Inc, and Monogram Biosciences, and as a member of data monitoring committees for Axio and Gilead Sciences, Inc. He has stock in Globelimmune, Inc.

Funding/Support: This work is supported and funded by the International Antiviral (formerly AIDS) Society–USA (IAS–USA), a mission-based, nonmembership, 501(c)(3) not-for-profit organization. The IAS–USA appointed members to the IAS–USA HIV Prevention Recommendations Panel to develop the recommendations and provided staff support. In the last 5 years, IAS–USA has received commercial support (grants) for selected continuing medical education (CME) activities that are pooled (ie, no single company supports any single effort) from Abbott Laboratories, AbbVie, Boehringer Ingelheim Pharmaceuticals, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Janssen Therapeutics, Merck & Co, Mylan, Pfizer, Salix Pharmaceuticals, Tibotec Therapeutics, Vertex Pharmaceuticals, and ViiV Healthcare. The designation of selected CME activities refers to the IAS–USA structure of accepting commercial support only if there are enough companies with competing products to meet the criteria for independence and only on programs appropriate for support by commercial sources (eg, recommendations are not supported by industry grants). No private sector funding was used to support the effort. Panel members are not compensated for participation in the effort.

Role of the Sponsor: The IAS–USA determined the need for updated recommendations, selected the panel members based on expertise in biomedical and behavioral HIV care and research, and provided administrative oversight and financial support. The panel is responsible for the design and conduct of the study; the collection, management, analysis, and interpretation of the data; the preparation, review, and approval of the manuscript; and the decision to submit the manuscript for publication.

Additional Contributions: The authors thank Jennifer R. Ham, MPH, IAS–USA, for administrative management of the development of the recommendations; Ms Ham was compensated as part of her employment. The authors also thank Margaret A. Fischl, MD, University of Miami, for initiating this effort and for her helpful review of the manuscript, and Chelsea B. Polis, PhD, US Agency for International Development, for her helpful review of the section on hormonal contraception.

Correction: This article was corrected online on July 19, 2014, to correct the group name and typographical errors.

REFERENCE

- Prejean J, Song R, Hernandez A, et al; HIV Incidence Surveillance Group. Estimated HIV incidence in the United States, 2006–2009. *PLoS One*. 2011;6(8):e17502.
- Fauci AS, Folkers GK, Dieffenbach CW. HIV-AIDS: much accomplished, much to do. *Nat Immunol*. 2013;14(11):1104–1107.
- American Academy of Pediatrics Task Force on Circumcision. Circumcision policy statement. *Pediatrics*. 2012;130(3):585–586.
- Canadian Task Force on the Periodic Health Examination. The periodic health examination. *Can Med Assoc J*. 1979;121(9):1193–1254.
- Centers for Disease Control and Prevention (CDC). Monitoring Selected National HIV Prevention and Care Objectives by Using HIV Surveillance Data—United States and 6 Dependent Areas—2011. CDC website. http://www.cdc.gov/hiv/pdf/2011_Monitoring_HIV_Indicators_HSSR_FINAL.pdf. Accessed May 23, 2014.
- Hall HI, Holtgrave DR, Tang T, Rhodes P. HIV transmission in the United States: considerations of viral load, risk behavior, and health disparities. *AIDS Behav*. 2013;17(5):1632–1636.
- Steward WT, Remien RH, Higgins JA, et al. Behavior change following diagnosis with acute/early HIV infection—a move to serosorting with other HIV-infected individuals. The NIMH Multisite Acute HIV Infection Study: III. *AIDS Behav*. 2009;13(6):1054–1060.
- Hall HI, Holtgrave DR, Maulsby C. HIV transmission rates from persons living with HIV who are aware and unaware of their infection. *AIDS*. 2012;26(7):893–896.
- Branson BM, Handsfield HH, Lampe MA, et al; Centers for Disease Control and Prevention (CDC). Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. *MMWR Recomm Rep*. 2006;55(RR-14):1–17, quiz CE1–CE4.
- Moyer VA; U.S. Preventive Services Task Force*. Screening for HIV: U.S. Preventive Services Task Force Recommendation Statement. *Ann Intern Med*. 2013;159(1):51–60.
- Food and Drug Administration (FDA). Complete List of Donor Screening Assays for Infectious Agents and HIV Diagnostic Assays. FDA website. <http://www.fda.gov/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/BloodDonorScreening/InfectiousDisease/UCMO80466>. Accessed May 23, 2014.
- Cornett JK, Kirn TJ. Laboratory diagnosis of HIV in adults: a review of current methods. *Clin Infect Dis*. 2013;57(5):712–718.
- Paltiel AD, Walensky RP. Home HIV testing: good news but not a game changer. *Ann Intern Med*. 2012;157(10):744–746.
- Branson BM, Stekler JD. Detection of acute HIV infection: we can't close the window. *J Infect Dis*. 2012;205(4):521–524.
- Centers for Disease Control and Prevention (CDC). Detection of acute HIV infection in two evaluations of a new HIV diagnostic testing algorithm—United States, 2011–2013. *MMWR Morb Mortal Wkly Rep*. 2013;62(24):489–494. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6224a2.htm?s_cid=mm6224a2_e. Accessed May 23, 2014.
- Workowski KA, Berman S; Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2010 [published correction appears in *MMWR Recomm Rep*. 2011;60(1):18]. *MMWR Recomm Rep*. 2010;59(RR-12):1–110.
- Sullivan PS, White D, Rosenberg ES, et al. Safety and acceptability of couples HIV testing and counseling for US men who have sex with men: a randomized prevention study. *J Int Assoc Provid AIDS Care*. 2014;13(2):135–144.
- World Health Organization (WHO). Guidance on Couples HIV Testing And Counselling—Including Antiretroviral Therapy for Treatment and Prevention in Serodiscordant Couples: Recommendations for a Public Health Approach. WHO website. http://apps.who.int/iris/bitstream/10665/44646/1/9789241501972_eng.pdf. Accessed May 23, 2014.
- Centers for Disease Control and Prevention (CDC). State HIV Laws. CDC website. <http://www.cdc.gov/hiv/policies/law/states/index.html>. Accessed May 23, 2014.
- Kamb ML, Fishbein M, Douglas JM Jr, et al; Project RESPECT Study Group. Efficacy of risk-reduction counseling to prevent human immunodeficiency virus and sexually transmitted diseases: a randomized controlled trial. *JAMA*. 1998;280(13):1161–1167.
- Bolu OO, Lindsey C, Kamb ML, et al; Project RESPECT Study Group. Is HIV/sexually transmitted disease prevention counseling effective among vulnerable populations?: a subset analysis of data collected for a randomized, controlled trial evaluating counseling efficacy (Project RESPECT). *Sex Transm Dis*. 2004;31(8):469–474.
- Weinhardt LS, Carey MP, Johnson BT, Bickham NL. Effects of HIV counseling and testing on sexual risk behavior: a meta-analytic review of published research, 1985–1997. *Am J Public Health*. 1999;89(9):1397–1405.
- Metsch LR, Feaster DJ, Gooden L, et al. Implementing rapid HIV testing with or without risk-reduction counseling in drug treatment centers: results of a randomized trial. *Am J Public Health*. 2012;102(6):1160–1167.
- Metcalfe CA, Douglas JM Jr, Malotte CK, et al; RESPECT-2 Study Group. Relative efficacy of prevention counseling with rapid and standard HIV testing: a randomized, controlled trial (RESPECT-2). *Sex Transm Dis*. 2005;32(2):130–138.
- Holtgrave D, McGuire J. Impact of counseling in voluntary counseling and testing programs for persons at risk for or living with HIV infection. *Clin Infect Dis*. 2007;45(suppl 4):S240–S243.
- Metcalfe CA, Malotte CK, Douglas JM Jr, et al; RESPECT-2 Study Group. Efficacy of a booster counseling session 6 months after HIV testing and counseling: a randomized, controlled trial (RESPECT-2). *Sex Transm Dis*. 2005;32(2):123–129.
- Metsch LR, Feaster DJ, Gooden L, et al. Effect of risk-reduction counseling with rapid HIV testing on risk of acquiring sexually transmitted infections: the AWARE randomized clinical trial. *JAMA*. 2013;310(16):1701–1710.
- Semaan S, Neumann MS, Hutchins K, D'Anna LH, Kamb ML; Project RESPECT Study Group. Brief counseling for reducing sexual risk and bacterial STIs among drug users—results from project RESPECT. *Drug Alcohol Depend*. 2010;106(1):7–15.

29. Dilley JW, Woods WJ, Sabatino J, et al. Changing sexual behavior among gay male repeat testers for HIV: a randomized, controlled trial of a single-session intervention. *J Acquir Immune Defic Syndr*. 2002;30(2):177-186.
30. Dilley JW, Woods WJ, Loeb L, et al. Brief cognitive counseling with HIV testing to reduce sexual risk among men who have sex with men: results from a randomized controlled trial using paraprofessional counselors. *J Acquir Immune Defic Syndr*. 2007;44(5):569-577.
31. Coffin PO, Santos GM, Colfax G, et al. Adapted personalized cognitive counseling for episodic substance-using men who have sex with men: a randomized controlled trial. *AIDS Behav*. 2014;18(7):1390-1400.
32. Sanders GD, Bayoumi AM, Sundaram V, et al. Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. *N Engl J Med*. 2005;352(6):570-585.
33. Paltiel AD, Weinstein MC, Kimmel AD, et al. Expanded screening for HIV in the United States--an analysis of cost-effectiveness. *N Engl J Med*. 2005;352(6):586-595.
34. Paltiel AD, Walensky RP, Schackman BR, et al. Expanded HIV screening in the United States: effect on clinical outcomes, HIV transmission, and costs. *Ann Intern Med*. 2006;145(11):797-806.
35. Rotheram-Borus MJ, Swendeman D, Comulada WS, Weiss RE, Lee M, Lightfoot M. Prevention for substance-using HIV-positive young people: telephone and in-person delivery. *J Acquir Immune Defic Syndr*. 2004;37(suppl 2):S68-S77.
36. Lightfoot M, Rotheram-Borus MJ, Tevendale H. An HIV-preventive intervention for youth living with HIV. *Behav Modif*. 2007;31(3):345-363.
37. El-Bassel N, Jemmott JB, Landis JR, et al; NIMH Multisite HIV/STD Prevention Trial for African American Couples Group. National Institute of Mental Health Multisite Eban HIV/STD Prevention Intervention for African American HIV Serodiscordant Couples: a cluster randomized trial. *Arch Intern Med*. 2010;170(17):1594-1601.
38. Healthy Living Project Team. Effects of a behavioral intervention to reduce risk of transmission among people living with HIV: the healthy living project randomized controlled study. *J Acquir Immune Defic Syndr*. 2007;44(2):213-221.
39. Kalichman SC, Rompa D, Cage M, et al. Effectiveness of an intervention to reduce HIV transmission risks in HIV-positive people. *Am J Prev Med*. 2001;21(2):84-92.
40. Kalichman SC, Cherry C, Kalichman MO, et al. Integrated behavioral intervention to improve HIV/AIDS treatment adherence and reduce HIV transmission. *Am J Public Health*. 2011;101(3):531-538.
41. Sikkema KJ, Wilson PA, Hansen NB, et al. Effects of a coping intervention on transmission risk behavior among people living with HIV/AIDS and a history of childhood sexual abuse. *J Acquir Immune Defic Syndr*. 2008;47(4):506-513.
42. Gilbert P, Ciccarone D, Gansky SA, et al. Interactive "Video Doctor" counseling reduces drug and sexual risk behaviors among HIV-positive patients in diverse outpatient settings. *PLoS One*. 2008;3(4):e1988.
43. Wolitski RJ, Gómez CA, Parsons JT. Effects of a peer-led behavioral intervention to reduce HIV transmission and promote serostatus disclosure among HIV-seropositive gay and bisexual men. *AIDS*. 2005;19(suppl 1):S99-S109.
44. McKirran DJ, Tolou-Shams M, Courtenay-Quirk C. The Treatment Advocacy Program: a randomized controlled trial of a peer-led safer sex intervention for HIV-infected men who have sex with men. *J Consult Clin Psychol*. 2010;78(6):952-963.
45. Wingood GM, DiClemente RJ, Mikhail I, et al. A randomized controlled trial to reduce HIV transmission risk behaviors and sexually transmitted diseases among women living with HIV: The WILLOW Program. *J Acquir Immune Defic Syndr*. 2004;37(suppl 2):S58-S67.
46. Fisher JD, Fisher WA, Cornman DH, Amico RK, Bryan A, Friedland GH. Clinician-delivered intervention during routine clinical care reduces unprotected sexual behavior among HIV-infected patients. *J Acquir Immune Defic Syndr*. 2006;41(1):44-52.
47. Richardson JL, Milam J, McCutchan A, et al. Effect of brief safer-sex counseling by medical providers to HIV-1 seropositive patients: a multi-clinic assessment. *AIDS*. 2004;18(8):1179-1186.
48. Golin CE, Earp JA, Grodensky CA, et al. Longitudinal effects of SafeTalk, a motivational interviewing-based program to improve safer sex practices among people living with HIV/AIDS. *AIDS Behav*. 2012;16(5):1182-1191.
49. Rotheram-Borus MJ, Lee MB, Murphy DA, et al; Teens Linked to Care Consortium. Efficacy of a preventive intervention for youths living with HIV. *Am J Public Health*. 2001;91(3):400-405.
50. Centers for Disease Control and Prevention (CDC). Listing of all risk reduction interventions, by characteristic. <http://www.cdc.gov/hiv/prevention/research/compendium/rr/characteristics.html>. Accessed on May 23, 2014.
51. Crepaz N, Tungol-Ashmon MV, Higa DH, et al. A systematic review of interventions for reducing HIV risk behaviors among people living with HIV in the United States, 1988-2012. *AIDS*. 2014;28(5):633-656.
52. Crosby R, DiClemente RJ, Charnigo R, Snow G, Troutman A. A brief, clinic-based, safer sex intervention for heterosexual African American men newly diagnosed with an STD: a randomized controlled trial. *Am J Public Health*. 2009;99(suppl 1):S96-S103.
53. Jemmott LS, Jemmott JB III, O'Leary A. Effects on sexual risk behavior and STD rate of brief HIV/STD prevention interventions for African American women in primary care settings. *Am J Public Health*. 2007;97(6):1034-1040.
54. James NJ, Gillies PA, Bignell CJ. Evaluation of a randomized controlled trial of HIV and sexually transmitted disease prevention in a genitourinary medicine clinic setting. *AIDS*. 1998;12(10):1235-1242.
55. Patterson TL, Mausbach B, Lozada R, et al. Efficacy of a brief behavioral intervention to promote condom use among female sex workers in Tijuana and Ciudad Juarez, Mexico. *Am J Public Health*. 2008;98(11):2051-2057.
56. Warner L, Klausner JD, Rietmeijer CA, et al; Safe in the City Study Group. Effect of a brief video intervention on incident infection among patients attending sexually transmitted disease clinics. *PLoS Med*. 2008;5(6):e135.
57. Shrier LA, Ancheta R, Goodman E, Chiou VM, Lyden MR, Emans SJ. Randomized controlled trial of a safer sex intervention for high-risk adolescent girls. *Arch Pediatr Adolesc Med*. 2001;155(1):73-79.
58. Attia S, Egger M, Müller M, Zwahlen M, Low N. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. *AIDS*. 2009;23(11):1397-1404.
59. Donnell D, Baeten JM, Kiarie J, et al; Partners in Prevention HSV/HIV Transmission Study Team. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. *Lancet*. 2010;375(9731):2092-2098.
60. Lu W, Zeng G, Luo J, et al. HIV transmission risk among serodiscordant couples: a retrospective study of former plasma donors in Henan, China. *J Acquir Immune Defic Syndr*. 2010;55(2):232-238.
61. Birungi J, Wang H, Ngolobe MH, et al. *Lack of effectiveness of antiretroviral therapy (ART) as an HIV prevention tool for serodiscordant couples in a rural ART program without viral load monitoring in Uganda*. Presented at: 19th International AIDS Conference (IAS); July 22-27, 2012; Washington, DC.
62. Montaner J, Hogg R. Implications of the Henan Province report on the treatment as prevention debate. *J Acquir Immune Defic Syndr*. 2011;56(3):e101-e102, author reply e101-e102.
63. Rodger A, Bruun T, Cambiano V, et al. *HIV transmission risk through condomless sex if HIV+ partner on suppressive ART: PARTNER study [Abstract 153LB]*. Presented at: 2014 Conference on Retroviruses and Opportunistic Infections; March 3-6, 2014; Boston, MA.
64. Cohen MS, Chen YQ, McCauley M, et al; HPTN 052 Study Team. Prevention of HIV-1 infection with early antiretroviral therapy. *N Engl J Med*. 2011;365(6):493-505.
65. Grinsztejn B, Hosseinipour MC, Ribaudo HJ, et al; HPTN 052-ACTG Study Team. Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial. *Lancet Infect Dis*. 2014;14(4):281-290.
66. Montaner JS, Lima VD, Barrios R, et al. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. *Lancet*. 2010;376(9740):532-539.
67. Tanser F, Barnighausen T, Grapsa E, Zaidi J, Newell ML. High coverage of ART associated with decline in risk of HIV acquisition in rural KwaZulu-Natal, South Africa. *Science*. 2013;339(6122):966-971.
68. Montaner JS. Expansion of HAART coverage is associated with sustained decreases in HIV/AIDS morbidity, mortality and HIV transmission--The "HIV Treatment as Prevention" experience in a Canadian setting. *PLoS ONE*. 2014;9(2):e87872.
69. US Department of State. PEPFAR Blueprint: Creating an AIDS-Free Generation. PEPFAR website. <http://www.pepfar.gov/documents/organization/201386.pdf>. Accessed May 23, 2014.
70. World Health Organization (WHO). Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. WHO website. http://apps.who.int/iris/bitstream/10665/85321/1/9789241505727_eng.pdf. Accessed on May 23, 2013.

71. Thompson MA, Aberg JA, Hoy JF, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. *JAMA*. 2012;308(4):387-402.
72. US Department of Health and Human Services and Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents: March 27, 2012. <http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf>. Accessed May 23, 2014.
73. Long EF, Brandeau ML, Owens DK. The cost-effectiveness and population outcomes of expanded HIV screening and antiretroviral treatment in the United States. *Ann Intern Med*. 2010;153(12):778-789.
74. Walensky RP, Ross EL, Kumarasamy N, et al. Cost-effectiveness of HIV treatment as prevention in serodiscordant couples. *N Engl J Med*. 2013;369(18):1715-1725.
75. Phillips AN, Cambiano V, Nakagawa F, et al. Increased HIV incidence in men who have sex with men despite high levels of ART-induced viral suppression: analysis of an extensively documented epidemic. *PLoS One*. 2013;8(2):e55312.
76. Brenner BG, Roger M, Stephens D, et al; Montreal PHI Cohort Study Group. Transmission clustering drives the onward spread of the HIV epidemic among men who have sex with men in Quebec. *J Infect Dis*. 2011;204(7):1115-1119.
77. Chibo D, Kaye M, Birch C. HIV transmissions during seroconversion contribute significantly to new infections in men who have sex with men in Australia. *AIDS Res Hum Retroviruses*. 2012;28(5):460-464.
78. Miller WC, Leone PA, McCoy S, Nguyen TQ, Williams DE, Pilcher CD. Targeted testing for acute HIV infection in North Carolina. *AIDS*. 2009;23(7):835-843.
79. Weintrob AC, Giner J, Menezes P, et al. Infrequent diagnosis of primary human immunodeficiency virus infection: missed opportunities in acute care settings. *Arch Intern Med*. 2003;163(17):2097-2100.
80. Powers KA, Ghani AC, Miller WC, et al. The role of acute and early HIV infection in the spread of HIV and implications for transmission prevention strategies in Lilongwe, Malawi: a modelling study. *Lancet*. 2011;378(9787):256-268.
81. Cohen MS, Dye C, Fraser C, Miller WC, Powers KA, Williams BG. HIV treatment as prevention: debate and commentary--will early infection compromise treatment-as-prevention strategies? *PLoS Med*. 2012;9(7):e1001232.
82. Pettifor A, MacPhail C, Corneli A, et al; NIAID Center for HIV/AIDS Vaccine Immunology. Continued high risk sexual behavior following diagnosis with acute HIV infection in South Africa and Malawi: implications for prevention. *AIDS Behav*. 2011;15(6):1243-1250.
83. Le T, Wright EJ, Smith DM, et al. Enhanced CD4+ T-cell recovery with earlier HIV-1 antiretroviral therapy. *N Engl J Med*. 2013;368(3):218-230.
84. Grinsztejn B, Hosseini-pour MC, Ribaudo H, et al. Effects of early versus delayed initiation of antiretroviral therapy on HIV clinical outcomes: results from the phase 3 HPTN 052 randomized controlled trial. *Lancet Infect Dis*. 2014;14(4):281-290.
85. Archin NM, Vaidya NK, Kuruc JD, et al. Immediate antiviral therapy appears to restrict resting CD4+ cell HIV-1 infection without accelerating the decay of latent infection. *Proc Natl Acad Sci U S A*. 2012;109(24):9523-9528.
86. Pati R, Lahuerta M, Elul B, et al; Identifying Optimal Models of HIV Care in Mozambique Study Group. Factors associated with loss to clinic among HIV patients not yet known to be eligible for antiretroviral therapy (ART) in Mozambique. *J Int AIDS Soc*. 2013;16:18490.
87. Thompson MA, Mugavero MJ, Amico KR, et al. Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: evidence-based recommendations from an International Association of Physicians in AIDS Care panel. *Ann Intern Med*. 2012;156(11):817-833, W-284, W-285, W-286, W-287, W-288, W-289, W-290, W-291, W-292, W-293, W-294.
88. Mathes T, Pieper D, Antoine SL, Eikermann M. Adherence-enhancing interventions for highly active antiretroviral therapy in HIV-infected patients - a systematic review. *HIV Med*. 2013;14(10):583-595.
89. Murphy DA, Marelich WD, Rappaport NB, Hoffman D, Farthing C. Results of an antiretroviral adherence intervention: STAR (Staying Healthy: Taking Antiretrovirals Regularly). *J Int Assoc Physicians AIDS Care (Chic)*. 2007;6(2):113-124.
90. Simoni JM, Wiebe JS, Saucedo JA, et al. A preliminary RCT of CBT-AD for adherence and depression among HIV-positive Latinos on the U.S.-Mexico border: the Nuevo Día study. *AIDS Behav*. 2013;17(8):2816-2829.
91. Simoni JM, Chen WT, Huh D, et al. A preliminary randomized controlled trial of a nurse-delivered medication adherence intervention among HIV-positive outpatients initiating antiretroviral therapy in Beijing, China. *AIDS Behav*. 2011;15(5):919-929.
92. Safren SA, O'Cleirigh C, Tan JY, et al. A randomized controlled trial of cognitive behavioral therapy for adherence and depression (CBT-AD) in HIV-infected individuals. *Health Psychol*. 2009;28(1):1-10.
93. Parsons JT, Rosof E, Punzalan JC, Di Maria L. Integration of motivational interviewing and cognitive behavioral therapy to improve HIV medication adherence and reduce substance use among HIV-positive men and women: results of a pilot project. *AIDS Patient Care STDS*. 2005;19(1):31-39.
94. Hill S, Kavookjian J. Motivational interviewing as a behavioral intervention to increase HAART adherence in patients who are HIV-positive: a systematic review of the literature. *AIDS Care*. 2012;24(5):583-592.
95. Golin CE, Earp J, Tien HC, Stewart P, Porter C, Howie L. A 2-arm, randomized, controlled trial of a motivational interviewing-based intervention to improve adherence to antiretroviral therapy (ART) among patients failing or initiating ART. *J Acquir Immune Defic Syndr*. 2006;42(1):42-51.
96. Gross R, Bellamy SL, Chapman J, et al. Managed problem solving for antiretroviral therapy adherence: a randomized trial. *JAMA Intern Med*. 2013;173(4):300-306.
97. Johnson MO, Dilworth SE, Taylor JM, Neilands TB. Improving coping skills for self-management of treatment side effects can reduce antiretroviral medication nonadherence among people living with HIV. *Ann Behav Med*. 2011;41(1):83-91.
98. Simoni JM, Pantalone DW, Plummer MD, Huang B. A randomized controlled trial of a peer support intervention targeting antiretroviral medication adherence and depressive symptomatology in HIV-positive men and women. *Health Psychol*. 2007;26(4):488-495.
99. Horvath KJ, Oakes JM, Rosser BR, et al. Feasibility, acceptability and preliminary efficacy of an online peer-to-peer social support ART adherence intervention. *AIDS Behav*. 2013;17(6):2031-2044.
100. Reznick OG, McCartney K, Gregorich SE, Zack B, Feaster DJ. An ecosystem-based intervention to reduce HIV transmission risk and increase medication adherence among inmates being released to the community. *J Correct Health Care*. 2013;19(3):178-193.
101. Letourneau EJ, Ellis DA, Naar-King S, Chapman JE, Cunningham PB, Fowler S. Multisystemic therapy for poorly adherent youth with HIV: results from a pilot randomized controlled trial. *AIDS Care*. 2013;25(4):507-514.
102. Himelhoch S, Medoff D, Maxfield J, et al. Telephone based cognitive behavioral therapy targeting major depression among urban dwelling, low income people living with HIV/AIDS: results of a randomized controlled trial. *AIDS Behav*. 2013;17(8):2756-2764.
103. Kalichman SC, Cherry C, Kalichman MO, et al. Randomized clinical trial of HIV treatment adherence counseling interventions for people living with HIV and limited health literacy. *J Acquir Immune Defic Syndr*. 2013;63(1):42-50.
104. Kalichman SC, Cherry J, Cain D. Nurse-delivered antiretroviral treatment adherence intervention for people with low literacy skills and living with HIV/AIDS. *J Assoc Nurses AIDS Care*. 2005;16(5):3-15.
105. Reynolds NR, Testa MA, Su M, et al; AIDS Clinical Trials Group 731 and 384 Teams. Telephone support to improve antiretroviral medication adherence: a multisite, randomized controlled trial. *J Acquir Immune Defic Syndr*. 2008;47(1):62-68.
106. Kalichman SC, Kalichman MO, Cherry C, et al. Brief behavioral self-regulation counseling for HIV treatment adherence delivered by cell phone: an initial test of concept trial. *AIDS Patient Care STDS*. 2011;25(5):303-310.
107. Wohl AR, Garland WH, Wu J, et al. A youth-focused case management intervention to engage and retain young gay men of color in HIV care. *AIDS Care*. 2011;23(8):988-997.
108. Binford MC, Kahana SY, Altice FL. A systematic review of antiretroviral adherence interventions for HIV-infected people who use drugs. *Curr HIV/AIDS Rep*. 2012;9(4):287-312.
109. Berg KM, Litwin A, Li X, Heo M, Arnsten JH. Directly observed antiretroviral therapy improves adherence and viral load in drug users attending methadone maintenance clinics: a randomized controlled trial. *Drug Alcohol Depend*. 2011;113(2-3):192-199.
110. Scott-Sheldon LA, Huedo-Medina TB, Warren MR, Johnson BT, Carey MP. Efficacy of behavioral interventions to increase condom use and reduce sexually transmitted infections: a meta-analysis,

- 1991 to 2010. *J Acquir Immune Defic Syndr*. 2011;58(5):489-498.
- 111.** Scott-Sheldon LA, Fielder RL, Carey MP. Sexual risk reduction interventions for patients attending sexually transmitted disease clinics in the United States: a meta-analytic review, 1986 to early 2009. *Ann Behav Med*. 2010;40(2):191-204.
- 112.** Johnson BT, Scott-Sheldon LA, Smoak ND, Lacroix JM, Anderson JR, Carey MP. Behavioral interventions for African Americans to reduce sexual risk of HIV: a meta-analysis of randomized controlled trials. *J Acquir Immune Defic Syndr*. 2009;51(4):492-501.
- 113.** Noar SM. Behavioral interventions to reduce HIV-related sexual risk behavior: review and synthesis of meta-analytic evidence. *AIDS Behav*. 2008;12(3):335-353.
- 114.** Herbst JH, Sherba RT, Crepaz N, et al; HIV/AIDS Prevention Research Synthesis Team. A meta-analytic review of HIV behavioral interventions for reducing sexual risk behavior of men who have sex with men. *J Acquir Immune Defic Syndr*. 2005;39(2):228-241.
- 115.** Soorapanth S, Chick SE. *Cost-utility analysis of behavioral interventions for HIV-infected persons to reduce HIV transmission in the US*. In: Johansson S, Jain S, Montayo-Torres J, Huga J, Yucusan E, eds. *Proceedings of the 2010 Winter Simulation Conference*. Baltimore, MD: 2013.
- 116.** Lee MB, Leibowitz A, Rotheram-Borus MJ. Cost-effectiveness of a behavioral intervention for seropositive youth. *AIDS Educ Prev*. 2005;17(2):105-118.
- 117.** Mizuno Y, Zhu J, Crepaz N, et al. Receipt of HIV/sexually transmitted disease prevention counseling by HIV-infected adults receiving medical care in the United States. *AIDS*. 2014;28(3):407-415.
- 118.** Naar-King S, Parsons JT, Johnson AM. Motivational interviewing targeting risk reduction for people with HIV: a systematic review. *Curr HIV/AIDS Rep*. 2012;9(4):335-343.
- 119.** Golin CE, Davis RA, Przybyla SM, et al. SafeTalk, a multicomponent, motivational interviewing-based, safer sex counseling program for people living with HIV/AIDS: a qualitative assessment of patients' views. *AIDS Patient Care STDS*. 2010;24(4):237-245.
- 120.** Kalichman SC, Cain D, Weinhardt L, et al. Experimental components analysis of brief theory-based HIV/AIDS risk-reduction counseling for sexually transmitted infection patients. *Health Psychol*. 2005;24(2):198-208.
- 121.** World Health Organization (WHO) and Joint United Nations Programme on HIV/AIDS. (UNAIDS). *Guidance for HIV Testing and Counselling and Care for Adolescents Living With HIV*. http://apps.who.int/iris/bitstream/10665/94334/1/9789241506168_eng.pdf. Accessed May 23, 2014.
- 122.** Napper LE, Fisher DG, Reynolds GL, Johnson ME. HIV risk behavior self-report reliability at different recall periods. *AIDS Behav*. 2010;14(1):152-161.
- 123.** Schroder KE, Carey MP, Venable PA. Methodological challenges in research on sexual risk behavior: II. Accuracy of self-reports. *Ann Behav Med*. 2003;26(2):104-123.
- 124.** National Network of STD/HIV Prevention Training Centers. Ask, screen, intervene: incorporating HIV prevention into the medical care of persons living with HIV. <http://nnpct.org/resources/asi-provider-card/>. Accessed May 23, 2014.
- 125.** Golden MR, Brewer DD, Kurth A, Holmes KK, Handsfield HH. Importance of sex partner HIV status in HIV risk assessment among men who have sex with men. *J Acquir Immune Defic Syndr*. 2004;36(2):734-742.
- 126.** Pathela P, Braunstein SL, Blank S, Schillinger JA. HIV incidence among men with and those without sexually transmitted rectal infections: estimates from matching against an HIV case registry. *Clin Infect Dis*. 2013;57(8):1203-1209.
- 127.** Blish CA, McClelland RS, Richardson BA, et al. Genital inflammation predicts HIV-1 shedding independent of plasma viral load and systemic inflammation. *J Acquir Immune Defic Syndr*. 2012;61(4):436-440.
- 128.** Wagner GA, Pacold ME, Kosakovsky Pond SL, et al. Incidence and prevalence of intrasubtype HIV-1 dual infection in at-risk men in the United States. *J Infect Dis*. 2014;209(7):1032-1038.
- 129.** Patton ME, Su JR, Nelson R, Weinstock H; Centers for Disease Control and Prevention (CDC). Primary and secondary syphilis—United States, 2005-2013. *MMWR Morb Mortal Wkly Rep*. 2014;63(18):402-406.
- 130.** Centers for Disease Control and Prevention (CDC). HIV-Specific Criminal Laws. CDC website. <http://www.cdc.gov/hiv/policies/law/states/exposure.html>. Accessed May 23, 2014.
- 131.** Taylor MM, Mickey T, Winscott M, James H, Kenney K, England B. Improving partner services by embedding disease intervention specialists in HIV-clinics. *Sex Transm Dis*. 2010;37(12):767-770.
- 132.** Golden MR, Dombrowski JC, Wood RW, Fleming M, Harrington RD. A controlled study of the effectiveness of public health HIV partner notification services. *AIDS*. 2009;23(1):133-135.
- 133.** The Well Project. Disclosure and HIV. The Well Project website. <http://www.thewellproject.org/hiv-information/disclosure-and-hiv>. Accessed May 23, 2014.
- 134.** World Health Organization. *UNODC, UNAIDS. Technical Guide for Countries to Set Targets for Universal Access to HIV Prevention, Treatment, and Care for Injecting Drug Users*. Geneva, Switzerland: World Health Organization; 2012.
- 135.** Strathdee SA, Hallett TB, Bobrova N, et al. HIV and risk environment for injecting drug users: the past, present, and future. *Lancet*. 2010;376(9737):268-284.
- 136.** Li J, Gilmour S, Zhang H, Koyanagi A, Shibuya K. The epidemiological impact and cost-effectiveness of HIV testing, antiretroviral treatment and harm reduction programs. *AIDS*. 2012;26(16):2069-2078.
- 137.** Milloy MJ, Montaner J, Wood E. Barriers to HIV treatment among people who use injection drugs: implications for 'treatment as prevention.' *Curr Opin HIV AIDS*. 2012;7(4):332-338.
- 138.** Uhlmann S, Milloy MJ, Kerr T, et al. Methadone maintenance therapy promotes initiation of antiretroviral therapy among injection drug users. *Addiction*. 2010;105(5):907-913.
- 139.** Palepu A, Milloy MJ, Kerr T, Zhang R, Wood E. Homelessness and adherence to antiretroviral therapy among a cohort of HIV-infected injection drug users. *J Urban Health*. 2011;88(3):545-555.
- 140.** Gowing L, Farrell M, Bornemann R, Sullivan L, Ali R. Substitution treatment of injecting opioid users for prevention of HIV infection. *Cochrane Database Syst Rev*. 2008;(2):CD004145.
- 141.** Fu TC, Westergaard RP, Lau B, et al. Changes in sexual and drug-related risk behavior following antiretroviral therapy initiation among HIV-infected injection drug users. *AIDS*. 2012;26(18):2383-2391.
- 142.** Marshall BD, Milloy MJ, Kerr T, Zhang R, Montaner JS, Wood E. No evidence of increased sexual risk behaviour after initiating antiretroviral therapy among people who inject drugs. *AIDS*. 2010;24(14):2271-2278.
- 143.** United Nations Office on Drugs and Crime (UNODC). *From Coercion to Cohesion: Treating Drug Dependence Through Health Care, Not Punishment* [Discussion paper]. UNODC website. http://www.unodc.org/docs/treatment/Coercion_Ebook.pdf. Accessed May 23, 2014.
- 144.** Neaigus A, Zhao M, Gyarmathy VA, Cisek L, Friedman SR, Baxter RC. Greater drug injecting risk for HIV, HBV, and HCV infection in a city where syringe exchange and pharmacy syringe distribution are illegal. *J Urban Health*. 2008;85(3):309-322.
- 145.** Wood E, Tyndall MW, Montaner JS, Kerr T. Summary of findings from the evaluation of a pilot medically supervised safer injecting facility. *CMAJ*. 2006;175(11):1399-1404.
- 146.** Milloy MJ, Kerr T, Tyndall M, Montaner J, Wood E. Estimated drug overdose deaths averted by North America's first medically-supervised safer injection facility. *PLoS One*. 2008;3(10):e3351.
- 147.** Wood E, Tyndall MW, Zhang R, et al. Attendance at supervised injecting facilities and use of detoxification services. *N Engl J Med*. 2006;354(23):2512-2514.
- 148.** Stoltz JA, Wood E, Small W, et al. Changes in injecting practices associated with the use of a medically supervised safer injection facility. *J Public Health (Oxf)*. 2007;29(1):35-39.
- 149.** Marshall BD, Wood E, Zhang R, Tyndall MW, Montaner JS, Kerr T. Condom use among injection drug users accessing a supervised injecting facility. *Sex Transm Infect*. 2009;85(2):121-126.
- 150.** Wood E, Tyndall MW, Lai C, Montaner JS, Kerr T. Impact of a medically supervised safer injecting facility on drug dealing and other drug-related crime. *Subst Abuse Treat Prev Policy*. 2006;1:13.
- 151.** Oviedo-Joekes E, Brissette S, Marsh DC, et al. Diacetylmorphine versus methadone for the treatment of opioid addiction. *N Engl J Med*. 2009;361(8):777-786.
- 152.** Nosyk B, Guh DP, Bansback NJ, et al. Cost-effectiveness of diacetylmorphine versus methadone for chronic opioid dependence refractory to treatment. *CMAJ*. 2012;184(6):317-328.
- 153.** Colfax GN, Santos GM, Das M, et al. Mirtazapine to reduce methamphetamine use: a randomized controlled trial. *Arch Gen Psychiatry*. 2011;68(11):1168-1175.
- 154.** Mausbach BT, Semple SJ, Strathdee SA, Zians J, Patterson TL. Efficacy of a behavioral intervention for increasing safer sex behaviors in HIV-positive MSM methamphetamine users: results

from the EDGE study. *Drug Alcohol Depend*. 2007; 87(2-3):249-257.

155. Gardner LI, Metsch LR, Anderson-Mahoney P, et al; Antiretroviral Treatment and Access Study Group. Efficacy of a brief case management intervention to link recently diagnosed HIV-infected persons to care. *AIDS*. 2005;19(4):423-431.

156. Gopalappa C, Farnham PG, Hutchinson AB, Sansom SL. Cost effectiveness of the National HIV/AIDS Strategy goal of increasing linkage to care for HIV-infected persons. *J Acquir Immune Defic Syndr*. 2012;61(1):99-105.

157. Walensky RP, Weinstein MC, Smith HE, Freedberg KA, Paltiel AD. Optimal allocation of testing dollars: the example of HIV counseling, testing, and referral. *Med Decis Making*. 2005;25(3):321-329.

158. Amorosa V, Synnstedt M, Gross R, et al. A tale of 2 epidemics: the intersection between obesity and HIV infection in Philadelphia. *J Acquir Immune Defic Syndr*. 2005;39(5):557-561.

159. Bonolo PdeF, César CC, Acúrcio FA, et al. Non-adherence among patients initiating antiretroviral therapy: a challenge for health professionals in Brazil. *AIDS*. 2005;19(suppl 4):S5-S13.

160. Andersen M, Paliwoda J, Kaczynski R, et al. Integrating medical and substance abuse treatment for addicts living with HIV/AIDS: evidence-based nursing practice model. *Am J Drug Alcohol Abuse*. 2003;29(4):847-859.

161. Fuchs J, Durham M, McLellan-Lemal E, et al. Negative social impacts among volunteers in an HIV vaccine efficacy trial. *J Acquir Immune Defic Syndr*. 2007;46(3):362-368.

162. Blankenship KM, Bray SJ, Merson MH. Structural interventions in public health. *AIDS*. 2000;14(suppl 1):S11-S21.

163. Craw JA, Gardner LI, Marks G, et al. Brief strengths-based case management promotes entry into HIV medical care: results of the antiretroviral treatment access study-II. *J Acquir Immune Defic Syndr*. 2008;47(5):597-606.

164. Hightow-Weidman LB, Smith JC, Valera E, Matthews DD, Lyons P. Keeping them in "STYLE": finding, linking, and retaining young HIV-positive black and Latino men who have sex with men in care. *AIDS Patient Care STDS*. 2011;25(1):37-45.

165. Farber S, Tate J, Frank C, et al. A study of financial incentives to reduce plasma HIV RNA among patients in care. *AIDS Behav*. 2013;17(7):2293-2300.

166. Bocour A, Renaud TC, Udeagu C-CN, Shepard CW. HIV partner services are associated with timely linkage to HIV medical care. *AIDS*. 2013;27(18):2961-2963.

167. Mugavero MJ, Amico KR, Westfall AO, et al. Early retention in HIV care and viral load suppression: implications for a test and treat approach to HIV prevention. *J Acquir Immune Defic Syndr*. 2012;59(1):86-93.

168. Metsch LR, Pereyra M, Messinger S, et al; Antiretroviral Treatment and Access Study (ARTAS) Study Group. HIV transmission risk behaviors among HIV-infected persons who are successfully linked to care. *Clin Infect Dis*. 2008;47(4):577-584.

169. Gardner LI, Giordano TP, Marks G, Wilson TE, et al; Retention in Care Study Group. Enhanced

personal contact with HIV patients improves retention in primary care: a randomized trial in six U.S. HIV clinics [published online May 15, 2014]. *Clin Infect Dis*. doi:10.1093/cid/ciu357.

170. Naar-King S, Outlaw A, Green-Jones M, Wright K, Parsons JT. Motivational interviewing by peer outreach workers: a pilot randomized clinical trial to retain adolescents and young adults in HIV care. *AIDS Care*. 2009;21(7):868-873.

171. Hightow-Weidman LB, Jones K, Wohl AR, et al; YMSM of Color SPNS Initiative Study Group. Early linkage and retention in care: findings from the outreach, linkage, and retention in care initiative among young men of color who have sex with men. *AIDS Patient Care STDS*. 2011;25(suppl 1):S31-S38.

172. Gardner LI, Marks G, Craw JA, et al; Retention in Care Study Group. A low-effort, clinic-wide intervention improves attendance for HIV primary care. *Clin Infect Dis*. 2012;55(8):1124-1134.

173. McCoy SI, Shiu K, Martz TE, et al. Improving the efficiency of HIV testing with peer recruitment, financial incentives, and the involvement of persons living with HIV infection. *J Acquir Immune Defic Syndr*. 2013;63(2):e56-e63.

174. Lucas GM, Chaudhry A, Hsu J, et al. Clinic-based treatment of opioid-dependent HIV-infected patients versus referral to an opioid treatment program: A randomized trial. *Ann Intern Med*. 2010;152(11):704-711.

175. Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, Puren A. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. *PLoS Med*. 2005;2(11):e298.

176. Gray RH, Kiwanuka N, Quinn TC, et al; Rakai Project Team. Male circumcision and HIV acquisition and transmission: cohort studies in Rakai, Uganda. *AIDS*. 2000;14(15):2371-2381.

177. Bailey RC, Muga R, Poulussen R, Abicht H. The acceptability of male circumcision to reduce HIV infections in Nyanza Province, Kenya. *AIDS Care*. 2002;14(1):27-40.

178. Baeten JM, Donnell D, Ndase P, et al; Partners PrEP Study Team. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. *N Engl J Med*. 2012;367(5):399-410.

179. Thigpen MC, Kebaabetswe PM, Paxton LA, et al; TDF2 Study Group. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. *N Engl J Med*. 2012;367(5):423-434.

180. Choopanya K, Martin M, Suntharasamai P, et al; Bangkok Tenofovir Study Group. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. *Lancet*. 2013;381(9883):2083-2090.

181. Grant RM, Lama JR, Anderson PL, et al; iPrEx Study Team. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. *N Engl J Med*. 2010;363(27):2587-2599.

182. Van Damme L, Corneli A, Ahmed K, et al; FEM-PrEP Study Group. Preexposure prophylaxis for HIV infection among African women. *N Engl J Med*. 2012;367(5):411-422.

183. Marrazzo JM, Ramjee G, Nair G, et al. Pre-exposure prophylaxis for HIV in women: daily oral tenofovir, oral tenofovir/emtricitabine or vaginal tenofovir gel in the VOICE study (MTN 003)

[Abstract 26LB]. Presented at: 20th Conference on Retroviruses and Opportunistic Infections (CROI); March 3-6, 2013; Atlanta, GA.

184. The White House Office of National AIDS Policy (ONAP). National HIV/AIDS Strategy for the United States. ONAP website. <http://www.whitehouse.gov/administration/eop/onap/>. Accessed May 23, 2014.

185. Holtgrave DR. On the epidemiologic and economic importance of the National AIDS Strategy for the United States. *J Acquir Immune Defic Syndr*. 2010;55(2):139-142.

186. Holtgrave DR, Hall HI, Wehrmeyer L, Maulsby C. Costs, consequences and feasibility of strategies for achieving the goals of the National HIV/AIDS strategy in the United States: a closing window for success? *AIDS Behav*. 2012;16(6):1365-1372.

187. Centers for Disease Control (CDC). High-impact HIV prevention CDC's approach to reducing HIV infections in the United States. CDC website. <http://www.cdc.gov/hiv/policies/hip.html>. Accessed May 23, 2014.

188. US Preventive Services Task Force (USPSTF). Behavioral counseling to prevent sexually transmitted infections. USPSTF website. <http://www.uspreventiveservicestaskforce.org/uspstf08/sti/stirs.htm>. Accessed May 23, 2014.

189. Eaton LA, Kalichman SC, Kenny DA, Harel O. A reanalysis of a behavioral intervention to prevent incident HIV infections: including indirect effects in modeling outcomes of Project EXPLORE. *AIDS Care*. 2013;25(7):805-811.

190. Koblin B, Chesney M, Coates T; EXPLORE Study Team. Effects of a behavioural intervention to reduce acquisition of HIV infection among men who have sex with men: the EXPLORE randomised controlled study. *Lancet*. 2004;364(9428):41-50.

191. Eaton LA, Huedo-Medina TB, Kalichman SC, et al. Meta-analysis of single-session behavioral interventions to prevent sexually transmitted infections: implications for bundling prevention packages. *Am J Public Health*. 2012;102(11):e34-e44.

192. Holtgrave DR, Maulsby C, Wehrmeyer L, Hall HI. Behavioral factors in assessing impact of HIV treatment as prevention. *AIDS Behav*. 2012;16(5):1085-1091.

193. Holtgrave DR, Hall HI, Des Jarlais DC, Mizuno Y, Purcell DW. Estimating number of diagnosed persons living with HIV in the United States engaged in unprotected serodiscordant risk behavior with unsuppressed viral load. *J Acquir Immune Defic Syndr*. 2014;65(3):e125-e128.

194. Rotheram-Borus MJ, Murphy DA, Coleman C, Swendeman D. Counseling adolescents: designing interventions to target routines, relationships, roles and stages of adaptation. In: Chesney MA, Antoni MH, eds. *Innovative Approaches to Health Psychology: Prevention and Treatment Lessons From AIDS*. Washington, DC: American Psychology Association; 2002:15-44.

195. Townsend L, Mathews C, Zembe Y. A systematic review of behavioral interventions to prevent HIV infection and transmission among heterosexual, adult men in low-and middle-income countries. *Prev Sci*. 2013;14(1):88-105.

196. Rotheram-Borus MJ, Swendeman D, Flannery D, Rice E, Adamson DM, Ingram B. Common factors in effective HIV prevention programs. *AIDS Behav*. 2009;13(3):399-408.

197. Centers for Disease Control and Prevention (CDC). Preexposure Prophylaxis for the Prevention of HIV Infection in the United States—2014: A Clinical Practice Guideline. CDC website. <http://www.cdc.gov/hiv/pdf/guidelines/PrEPguidelines2014.pdf>. Accessed May 23, 2014.
198. Anderson PL, Glidden DV, Liu A, et al; iPrEx Study Team. Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. *Sci Transl Med*. 2012;4(151):ra125.
199. García-Lerma JG, Cong ME, Mitchell J, et al. Intermittent prophylaxis with oral truvada protects macaques from rectal SHIV infection. *Sci Transl Med*. 2010;2(14):ra4.
200. Spreen W, Williams P, Margolis D, et al. *First study of repeat dose co-administration of GSK1265744 and TMC278 long-acting parenteral nanosuspensions: pharmacokinetics, safety and tolerability in healthy adults [Abstract WEABO103]*. Presented at: 7th IAS Conference on HIV Pathogenesis, Treatment and Prevention; June 30-July 3, 2013; Kuala Lumpur, Malaysia.
201. Abdool Karim SS, Richardson BA, Ramjee G, et al; HIV Prevention Trials Network (HPTN) 035 Study Team. Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women. *AIDS*. 2011;25(7):957-966.
202. Paltiel AD, Freedberg KA, Scott CA, et al. HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. *Clin Infect Dis*. 2009;48(6):806-815.
203. Juusola JL, Brandeau ML, Owens DK, Bendavid E. The cost-effectiveness of preexposure prophylaxis for HIV prevention in the United States in men who have sex with men. *Ann Intern Med*. 2012;156(8):541-550.
204. García-Lerma JG, Heneine W. Animal models of antiretroviral prophylaxis for HIV prevention. *Curr Opin HIV AIDS*. 2012;7(6):505-513.
205. Cardo DM, Culver DH, Ciesielski CA, et al; Centers for Disease Control and Prevention Needlestick Surveillance Group. A case-control study of HIV seroconversion in health care workers after percutaneous exposure. *N Engl J Med*. 1997;337(21):1485-1490.
206. Kuhar DT, Henderson DK, Struble KA, et al; US Public Health Service Working Group. Updated US Public Health Service guidelines for the management of occupational exposures to human immunodeficiency virus and recommendations for postexposure prophylaxis [published correction appears in *Infect Control Hosp Epidemiol*. 2013;34(11):1238]. *Infect Control Hosp Epidemiol*. 2013;34(9):875-892.
207. Smith DK, Grohskopf LA, Black RJ, et al; U.S. Department of Health and Human Services. Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States: recommendations from the U.S. Department of Health and Human Services. *MMWR Recomm Rep*. 2005;54(RR-2):1-20.
208. Schechter M, do Lago RF, Mendelsohn AB, Moreira RI, Moulton LH, Harrison LH; Praca Onze Study Team. Behavioral impact, acceptability, and HIV incidence among homosexual men with access to postexposure chemoprophylaxis for HIV. *J Acquir Immune Defic Syndr*. 2004;35(5):519-525.
209. Poynten IM, Jin F, Mao L, et al. Nonoccupational postexposure prophylaxis, subsequent risk behaviour and HIV incidence in a cohort of Australian homosexual men. *AIDS*. 2009;23(9):1119-1126.
210. Landovitz RJ, Currier JS. Clinical practice. Postexposure prophylaxis for HIV infection. *N Engl J Med*. 2009;361(18):1768-1775.
211. Tsai CC, Emau P, Follis KE, et al. Effectiveness of postinoculation (R)-9-(2-phosphonylmethoxypropyl) adenine treatment for prevention of persistent simian immunodeficiency virus SIVmne infection depends critically on timing of initiation and duration of treatment. *J Virol*. 1998;72(5):4265-4273.
212. Mayer KH, Mimiaga MJ, Cohen D, et al. Tenofovir DF plus lamivudine or emtricitabine for nonoccupational postexposure prophylaxis (NPEP) in a Boston Community Health Center. *J Acquir Immune Defic Syndr*. 2008;47(4):494-499.
213. Mayer KH, Mimiaga MJ, Gelman M, Grasso C. Raltegravir, tenofovir DF, and emtricitabine for postexposure prophylaxis to prevent the sexual transmission of HIV: safety, tolerability, and adherence. *J Acquir Immune Defic Syndr*. 2012;59(4):354-359.
214. Bassett IV, Freedberg KA, Walensky RP. Two drugs or three? Balancing efficacy, toxicity, and resistance in postexposure prophylaxis for occupational exposure to HIV. *Clin Infect Dis*. 2004;39(3):395-401.
215. Diaz-Brito V, León A, Knobel H, et al; DATEMPEP study group. Post-exposure prophylaxis for HIV infection: a clinical trial comparing lopinavir/ritonavir versus atazanavir each with zidovudine/lamivudine. *Antivir Ther*. 2012;17(2):337-346.
216. Roland ME, Neilands TB, Krone MR, et al. Seroconversion following nonoccupational postexposure prophylaxis against HIV. *Clin Infect Dis*. 2005;41(10):1507-1513.
217. Nagelkerke NJ, Moses S, de Vlas SJ, Bailey RC. Modelling the public health impact of male circumcision for HIV prevention in high prevalence areas in Africa. *BMC Infect Dis*. 2007;7:16.
218. Auvert B, Taljaard D, Rech D, et al. Association of the ANRS-12126 male circumcision project with HIV levels among men in a South African township: evaluation of effectiveness using cross-sectional surveys. *PLoS Med*. 2013;10(9):e1001509.
219. Long EF, Stavert RR. Portfolios of biomedical HIV interventions in South Africa: a cost-effectiveness analysis. *J Gen Intern Med*. 2013;28(10):1294-1301.
220. Mehta SD, Moses S, Agot K, et al. The long term efficacy of medical male circumcision against HIV acquisition [published online July 3, 2013]. *AIDS*. doi:10.1097/O1.aids.0000432444.30308.2d.
221. Tobian AA, Kong X, Wawer MJ, et al. Circumcision of HIV-infected men and transmission of human papillomavirus to female partners: analyses of data from a randomised trial in Rakai, Uganda. *Lancet Infect Dis*. 2011;11(8):604-612.
222. Tobian AA, Sempijija V, Kigozi G, et al. Incident HIV and herpes simplex virus type 2 infection among men in Rakai, Uganda. *AIDS*. 2009;23(12):1589-1594.
223. Wawer MJ, Makumbi F, Kigozi G, et al. Circumcision in HIV-infected men and its effect on HIV transmission to female partners in Rakai, Uganda: a randomised controlled trial. *Lancet*. 2009;374(9685):229-237.
224. Hallett TB, Alsaqa RA, Baeten JM, et al. Will circumcision provide even more protection from HIV to women and men? New estimates of the population impact of circumcision interventions. *Sex Transm Infect*. 2011;87(2):88-93.
225. Mavhu W, Hatzold K, Laver SM, et al. Acceptability of early infant male circumcision as an HIV prevention intervention in Zimbabwe: a qualitative perspective. *PLoS One*. 2012;7(2):e32475.
226. Gebremedhin S. Assessment of the protective effect of male circumcision from HIV infection and sexually transmitted diseases: evidence from 18 demographic and health surveys in Sub-Saharan Africa. *East Afr J Public Health*. 2010;7(4):295-299.
227. Lissouba P, Taljaard D, Rech D, et al. A model for the roll-out of comprehensive adult male circumcision services in African low-income settings of high HIV incidence: the ANRS 12126 Bophelo Pele Project. *PLoS Med*. 2010;7(7):e1000309.
228. Young MR, Bailey RC, Odoyo-June E, et al. Safety of over twelve hundred infant male circumcisions using the Mogen clamp in Kenya. *PLoS One*. 2012;7(10):e47395.
229. Ford N, Chu K, Mills EJ. Safety of task-shifting for male medical circumcision: a systematic review and meta-analysis. *AIDS*. 2012;26(5):559-566.
230. Justman J, Goldberg A, Reed J, Bock N, Njehumeli E, Goldzier Thomas A. Adult male circumcision: reflections on successes and challenges. *J Acquir Immune Defic Syndr*. 2013;63(suppl 2):S140-S143.
231. Sánchez J, Sal Y Rosas VG, Hughes JP, et al. Male circumcision and risk of HIV acquisition among MSM. *AIDS*. 2011;25(4):519-523.
232. Hughes JP, Baeten JM, Lingappa JR, et al; Partners in Prevention HSV/HIV Transmission Study Team. Determinants of per-coital-act HIV-1 infectivity among African HIV-1-serodiscordant couples. *J Infect Dis*. 2012;205(3):358-365.
233. Jin F, Prestage GP, Imrie J, et al. Anal sexually transmitted infections and risk of HIV infection in homosexual men. *J Acquir Immune Defic Syndr*. 2010;53(1):144-149.
234. Aberg JA, Gallant JE, Ghanem KG, Emmanuel P, Zingman BS, Horberg MA. Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV Medicine Association of the Infectious Diseases Society of America. *Clin Infect Dis*. 2014;58(1):1-10.
235. Wandeler G, Sponser T, Bregenger A, et al; Swiss HIV Cohort Study. Hepatitis C virus infections in the Swiss HIV Cohort Study: a rapidly evolving epidemic. *Clin Infect Dis*. 2012;55(10):1408-1416.
236. Centers for Disease Control (CDC) Division of STD Prevention. Sexually transmitted disease surveillance 2011. CDC website. <http://www.cdc.gov/std/stats11/Surv2011.pdf>. Accessed December 2012. May 23, 2014.
237. Mayer KH, Bush T, Henry K, et al; SUN Investigators. Ongoing sexually transmitted disease acquisition and risk-taking behavior among US HIV-infected patients in primary care: implications for prevention interventions. *Sex Transm Dis*. 2012;39(1):1-7.

- 238.** Garg S, Taylor LE, Grasso C, Mayer KH. Prevalent and incident hepatitis C virus infection among HIV-infected men who have sex with men engaged in primary care in a Boston community health center. *Clin Infect Dis*. 2013;56(10):1480-1487.
- 239.** Patton ME, Kidd S, Llata E, et al. Extragenital gonorrhea and chlamydia testing and infection among men who have sex with men—STD Surveillance Network, United States, 2010-2012. *Clin Infect Dis*. 2014;58(11):1564-1570.
- 240.** Hoover KW, Butler M, Workowski K, et al; Evaluation Group for Adherence to STD and Hepatitis Screening. STD screening of HIV-infected MSM in HIV clinics. *Sex Transm Dis*. 2010;37(12):771-776.
- 241.** Centers for Disease Control and Prevention (CDC). Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). CDC website. <http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5602a1.htm>. Accessed May 23, 2014.
- 242.** Kahn JA, Xu J, Kapogiannis BG, et al. Immunogenicity and safety of the human papillomavirus 6, 11, 16, 18 vaccine in HIV-infected young women. *Clin Infect Dis*. 2013;57(5):735-744.
- 243.** Wilkin T, Lee JY, Lensing SY, et al. Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men. *J Infect Dis*. 2010;202(8):1246-1253.
- 244.** Polis CB, Phillips SJ, Curtis KM. Hormonal contraceptive use and female-to-male HIV transmission: a systematic review of the epidemiologic evidence. *AIDS*. 2013;27(4):493-505.
- 245.** Phillips SJ, Curtis KM, Polis CB. Effect of hormonal contraceptive methods on HIV disease progression: a systematic review. *AIDS*. 2013;27(5):787-794.
- 246.** Polis CB, Curtis KM. Use of hormonal contraceptives and HIV acquisition in women: a systematic review of the epidemiological evidence. *Lancet Infect Dis*. 2013;13(9):797-808.
- 247.** Butler AR, Smith JA, Polis CB, Gregson S, Stanton D, Hallett TB. Modelling the global competing risks of a potential interaction between injectable hormonal contraception and HIV risk. *AIDS*. 2013;27(1):105-113.
- 248.** Noguchi LM, Richardson B, Chirenje ZM, et al. Injectable contraception and HIV acquisition in the VOICE study (MTN-003) [CROI abstract 847]. *Top Antivir Med*. 2014;22(special issue e-1):441.
- 249.** World Health Organization (WHO) Department of Reproductive Health and Research. Hormonal Contraception and HIV: Technical Statment. WHO website. http://whqlibdoc.who.int/hq/2012/WHO_RHR_12.08_eng.pdf. February 16, 2012. Accessed May 23, 2014.
- 250.** Centers for Disease Control and Prevention (CDC). Update to CDC's U.S. Medical Eligibility Criteria for Contraceptive Use, 2010: revised recommendations for the use of hormonal contraception among women at high risk for HIV infection or infected with HIV. *MMWR Morb Mortal Wkly Rep*. 2012;61(24):449-452.